Nephros (NEPH) 10-K15 Apr 152014 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Dec. 31, 2014	Apr. 14, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	NEPHROS INC
Entity Central Index Key	1196298
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$15,004,000
Trading Symbol	NEPH
Entity Common Stock, Shares Outstanding		30,393,640

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash	$1,284	$579
Accounts receivable, net	110	122
Inventory, net	186	162
Prepaid expenses and other current assets	104	125
Total current assets	1,684	988
Property and equipment, net	1	7
Other assets, net of accumulated amortization	1,684	1,894
Total assets	3,369	2,889
Current liabilities:
Senior secured note payable, net of debt discount of $142 at December 31, 2013	0	1,358
Accounts payable	835	1,073
Accrued expenses	342	365
Deferred revenue, current portion	70	703
Total current liabilities	1,247	3,499
Warrant liability	7,386	3,109
Long-term portion of deferred revenue	417	0
Total liabilities	9,050	6,608
Commitments and Contingencies
Stockholders' deficit:
Preferred stock, $.001 par value; 5,000,000 shares authorized at December 31, 2014 and 2013; no shares issued and outstanding at December 31, 2014 and 2013.	0	0
Common stock, $.001 par value; 90,000,000 shares authorized at December 31, 2014 and 2013; 30,391,513 and 18,082,043 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively.	30	18
Additional paid-in capital	108,382	102,983
Accumulated other comprehensive income	72	74
Accumulated deficit	-114,165	-106,794
Total stockholders' deficit	-5,681	-3,719
Total liabilities and stockholders' deficit	$3,369	$2,889

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Senior Secured Note, Debt Discount Amount		$142
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	30,391,513	18,082,043
Common stock, shares outstanding	30,391,513	18,082,043

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Net revenue:
Product revenues	$914	$1,029
Licensing revenues	834	711
Total net revenues	1,748	1,740
Cost of goods sold	549	898
Gross margin	1,199	842
Operating expenses:
Research and development	781	867
Depreciation and amortization	217	223
Selling, general and administrative	2,870	3,069
Total operating expenses	3,868	4,159
Loss from operations	-2,669	-3,317
Change in fair value of warrant liability	-4,277	5,020
Interest expense	-483	-351
Gain on sale of equipment	0	3
Other income (expense), net	58	-33
Net income (loss)	-7,371	1,322
Other comprehensive loss, foreign currency translation adjustments	-2	-2
Total comprehensive income (loss)	($7,373)	$1,320
Net income (loss) per common share, basic	($0.31)	$0.08
Weighted average common shares outstanding, basic	23,817,184	15,624,999
Net loss per common share, diluted	($0.31)	($0.18)
Weighted average common shares outstanding, diluted	23,817,184	20,760,410

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
In Thousands, except Share data	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	($8,724)	$12	$99,304	$76	($108,116)
Balance, shares at Dec. 31, 2012		11,949,824
Net income, as restated	1,322				1,322
Net unrealized losses on foreign currency translation, net of tax	-2			-2
Shareholder rights offerings, net	2,771	5	2,766
Shareholder rights offering net shares		5,000,000
Issuance of restricted stock	0
Issuance of restricted stock, shares		340,220
Exercise of warrants	248	1	247
Exercise of warrants, shares		791,999
Noncash stock-based compensation	652		652
Warrant modification	14		14
Balance at Dec. 31, 2013	-3,719	18	102,983	74	-106,794
Balance, shares at Dec. 31, 2013		18,082,043
Net income, as restated	-7,371				-7,371
Net unrealized losses on foreign currency translation, net of tax	-2			-2
Shareholder rights offerings, net	4,866	12	4,854
Shareholder rights offering net shares		12,140,823
Issuance of restricted stock	0		0
Issuance of restricted stock, shares		132,077
Exercise of warrants	15		15
Exercise of warrants, shares		36,570
Noncash stock-based compensation	530		530
Balance at Dec. 31, 2014	($5,681)	$30	$108,382	$72	($114,165)
Balance, shares at Dec. 31, 2014		30,391,513

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Operating activities
Net income (loss)	($7,371)	$1,322
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation of property and equipment	6	9
Amortization of other assets	210	214
Non-cash stock-based compensation, including stock options and restricted stock	429	575
Change in fair value of warrant liability	4,277	-5,020
Warrant inducement	0	14
Inventory reserve	59	210
Amortization of debt discount	320	257
Gain on disposal of property and equipment	0	-3
(Gain)/loss on foreign currency transactions	-48	26
(Increase) decrease in operating assets:
Accounts receivable	12	820
Inventory	-82	-60
Prepaid expenses and other current assets	21	-16
Increase (decrease) in operating liabilities:
Accounts payable	-190	-23
Accrued expenses	78	121
License and supply agreement fee payable	0	-1,318
Deferred revenue	-216	-711
Net cash used in operating activities	-2,495	-3,583
Investing activities
Proceeds from sales of property and equipment	0	3
Net cash provided by investing activities	0	3
Financing activities
Proceeds from issuance of common stock, net of equity issuance costs of $276 and $229, respectively	4,866	2,771
Proceeds from issuance of senior secured notes	1,572	2,800
Payment of financing costs	0	-399
Proceeds from exercise of warrants	15	248
Payment of senior secured notes	-3,250	-1,300
Net cash provided by financing activities	3,203	4,120
Effect of exchange rates on cash	-3	-8
Net increase in cash	705	532
Cash, beginning of year	579	47
Cash, end of year	1,284	579
Supplemental disclosure of cash flow information
Cash paid for interest	188	54
Cash paid for taxes	6	2
Restricted stock issued to settle liability	$101	$77

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Payments of Stock Issuance Costs	$276	$229

Organization_and_Nature_of_Ope

Organization and Nature of Operations	12 Months Ended
Organization and Nature of Operations	Dec. 31, 2014
Organization and Nature of Operations [Abstract]
Organization and Nature of Operations	Note 1 - Organization and Nature of Operations

	Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. Nephros was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced End Stage Renal Disease (“ESRD”) therapy technology and products. The Company has two products in the hemodiafiltration, or HDF, modality to deliver therapy for ESRD patients. These are the OLpūr mid-dilution HDF filter or “dialyzer,” designed expressly for HDF therapy, and the OLpūr H2H HDF module, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy. In 2009, the Company introduced its Dual Stage Ultrafilter (“DSU”) water filter, which represented a new and complementary product line to the Company’s ESRD therapy business. The DSU incorporates the Company’s unique and proprietary dual stage filter architecture.

	On June 4, 2003, Nephros International Limited was incorporated under the laws of Ireland as a wholly-owned subsidiary of the Company. In August 2003, the Company established a European Customer Service and financial operations center in Dublin, Ireland.

	The U.S. facilities, located at 41 Grand Avenue, River Edge, New Jersey, 07661, are used to house the Company’s corporate headquarters and research facilities.

Restatement_of_Previously_Issu

Restatement of Previously Issued Financial Statements	12 Months Ended
Restatement of Previously Issued Financial Statements	Dec. 31, 2014
Accounting Changes and Error Corrections [Abstract]
Accounting Changes and Error Corrections	Note 2 – Restatement of Previously Issued Financial Statements

	In preparation of the Annual Report, the Company concluded it should correct its accounting related to the Company’s outstanding warrants that were originally issued in 2007 (the “2007 Warrants”). The Company had initially accounted for the warrants as a component of equity but upon further evaluation of the terms of these warrants, concluded that the 2007 Warrants should be accounted for as a derivative liability. The Company’s 2007 Warrants are not indexed to the Company’s common stock because the transactions that would trigger the Anti-Dilution Adjustment Provision are not inputs to the fair value of the warrants. As a result, we should have classified the 2007 Warrants as derivative liabilities as of January 1, 2009, the date which ASC Section 815-40-15 was effective. Under this accounting treatment, we are required to measure the fair value of the 2007 Warrants at the end of each reporting period beginning in the year ended December 31, 2009, with a cumulative effect presented as of January 1, 2009, and recognize changes in the fair value for all periods beginning with January 1, 2009 in our operating results for the current period.

	The following table summarizes the effect of the restatement to the Company’s financial statements for (i) its audited consolidated financial statements as of and for the years ended December 31, 2013, 2012, 2011, 2010 and 2009, including the cumulative effect as of January 1, 2009, and (ii) its unaudited condensed consolidated interim financial statements as of, and for each of the quarterly periods ended, March 31, June 30, and September 30, in the years 2014 and 2013:

				(Amounts in 000s, except share and per share data)
			As
			Previously						As
			Reported			Adjustments			Restated

	Balance sheet as of September 30, 2014 (unaudited)
	Warrant Liability		$	-		$	7,116		$	7,116
	Additional Paid-in Capital			102,864			2,458			105,322
	Accumulated Deficit			-103,348			-9,573			-112,921

	Three months ended September 30, 2014 (unaudited)
	Change in fair value of warrant liability			-			3,428			3,428
	Net income (loss)			-706			3,428			2,723
	Net income (loss) per share, basic			-0.03			0.14			0.11
	Net income (loss) per share, diluted			-0.03			0.01			-0.02
	Weighted average common shares outstanding, diluted			25,238,412			8,252,777			33,491,189
	Comprehensive income (loss)			-705			3,429			2,724


				(Amounts in 000s, except share and per share data)
			As
			Previously						As
			Reported			Adjustments			Restated

	Nine months ended September 30, 2014 (unaudited)
	Change in fair value of warrant liability			-			-4,007			-4,007
	Net loss			-2,120			-4,007			-6,127
	Net income (loss) per share, basic and diluted			-0.09			-0.18			-0.27
	Comprehensive loss			-2,121			-4,007			-6,128

	Balance sheet as of June 30, 2014 (unaudited)
	Warrant Liability			-			10,544			10,544
	Additional Paid-in Capital			102,761			2,458			105,219
	Accumulated Deficit			-102,642			-13,002			-115,644

	Three months ended June 30, 2014 (unaudited)
	Change in fair value of warrant liability			-			-4,685			-4,685
	Net loss			-654			-4,685			-5,339
	Net loss per share, basic and diluted			-0.03			-0.18			-0.21
	Comprehensive loss			-655			-4,685			-5,340

	Six months ended June 30, 2014 (unaudited)
	Change in fair value of warrant liability			-			-7,436			-7,436
	Net loss			-1,414			-7,436			-8,850
	Net loss per share, basic and diluted			-0.06			-0.34			-0.4
	Comprehensive loss			-1,416			-7,436			-8,852

	Balance sheet as of March 31, 2014 (unaudited)
	Warrant Liability			-			5,859			5,859
	Additional Paid-in Capital			102,656			2,458			105,114
	Accumulated Deficit			-101,988			-8,317			-110,305

	Three months ended March 31, 2014 (unaudited)
	Change in fair value of warrant liability			-			-2,751			-2,751
	Net loss			-760			-2,751			-3,511
	Net loss per share, basic and diluted			-0.04			-0.15			-0.19
	Comprehensive loss			-761			-2,751			-3,512

Balance sheet as of December 31, 2013 (audited)
Warrant Liability			-			3,109			3,109
Additional Paid-in Capital			100,526			2,457			102,983
Accumulated Deficit			-101,228			-5,566			-106,794


			(Amounts in 000s, except share and per share data)
		As
		Previously						As
		Reported			Adjustments			Restated

Year ended December 31, 2013 (audited)
Change in fair value of warrant liability			-			5,020			5,020
Net income (loss)			-3,698			5,020			1,322
Net income (loss) per share, basic			-0.24			0.32			0.08
Net income (loss) per share, diluted			-0.24			0.06			-0.18
Weighted average common shares outstanding, diluted			15,624,999			5,135,411			20,760,410
Comprehensive income (loss)			-3,700			5,020			1,320

Balance sheet as of September 30, 2013 (unaudited)
Warrant Liability			-			7,776			7,776
Additional Paid-in Capital			100,391			2,457			102,848
Accumulated Deficit			-100,053			-10,234			-110,287

Three months ended September 30, 2013 (unaudited)
Change in fair value of warrant liability			-			-1,797			-1,797
Net loss			-611			-1,797			-2,408
Net loss per share, basic and diluted			-0.03			-0.11			-0.14
Comprehensive loss			-611			-1,797			-2,408

Nine months ended September 30, 2013 (unaudited)
Change in fair value of warrant liability			-			352			352
Net income (loss)			-2,523			352			-2,171
Net income (loss) per share, basic and diluted			-0.17			0.02			-0.15
Comprehensive loss			-2,525			352			-2,173

Balance sheet as of June 30, 2013 (unaudited)
Warrant Liability			-			5,980			5,980
Additional Paid-in Capital			100,191			2,457			102,648
Accumulated Deficit			-99,442			-8,437			-107,879

Three months ended June 30, 2013 (unaudited)
Change in fair value of warrant liability			-			-608			-608
Net loss			-671			-608			-1,279
Net loss per share, basic and diluted			-0.05			-0.05			-0.1
Comprehensive loss			-673			-608			-1,281

Six months ended June 30, 2013 (unaudited)
Change in fair value of warrant liability			-			2,149			2,149
Net income (loss)			-1,912			2,149			237
Net income (loss) per share, basic			-0.14			0.16			0.02
Net income (loss) per share, diluted			-0.14			0.04			-0.1
Weighted average common shares outstanding, diluted			14,556,050			5,150,160			19,706,210
Comprehensive income (loss)			-1,914			2,149			235

			(Amounts in 000s, except share and per share data)
		As
		Previously						As
		Reported			Adjustments			Restated

Balance sheet as of March 31, 2013 (unaudited)
Warrant Liability			-			5,372			5,372
Additional Paid-in Capital			96,988			2,457			99,445
Accumulated Deficit			-98,772			-7,830			-106,602

Three months ended March 31, 2013 (unaudited)
Change in fair value of warrant liability			-			2,756			2,756
Net income (loss)			-1,242			2,756			1,514
Net income (loss) per share, basic			-0.1			0.23			0.13
Net income (loss) per share, diluted			-0.1			0.03			-0.07
Weighted average common shares outstanding, diluted			12,009,285			5,624,075			17,633,360
Comprehensive income (loss)			-1,242			2,756			1,514

Balance sheet as of December 31, 2012 (audited)
Warrant Liability			-			8,129			8,129
Additional Paid-in Capital			96,847			2,457			99,304
Accumulated Deficit			-97,530			-10,586			-108,116

Year ended December 31, 2012 (audited)
Change in fair value of warrant liability			-			-3,361			-3,361
Net loss			-3,262			-3,361			-6,623
Net loss per share, basic and diluted			-0.29			-0.3			-0.59
Comprehensive loss			-3,262			-3,361			-6,596

Balance sheet as of December 31, 2011 (audited)
Warrant Liability			-			5,096			5,096
Additional Paid-in Capital			95,630			2,129			97,759
Accumulated Deficit			-94,268			-7,225			-101,493

Year ended December 31, 2011 (audited)
Change in fair value of warrant liability			-			-4,638			-4,638
Net loss			-2,360			-4,638			-6,998
Net loss per share, basic and diluted			-0.27			-0.54			-0.81
Comprehensive loss			-2,333			-4,638			-6,971

Balance sheet as of December 31, 2010 (audited)
Warrant Liability			-			458			458
Additional Paid-in Capital			91,979			2,129			94,108
Accumulated Deficit			-91,908			-2,587			-94,495

			(Amounts in 000s, except share and per share data)
		As
		Previously						As
		Reported			Adjustments			Restated

Year ended December 31, 2010 (audited)
Change in fair value of warrant liability			-			5,813			5,813
Net income (loss)			-1,933			5,813			3,880
Net income (loss) per share, basic and diluted			-0.93			2.79			1.86

Balance sheet as of December 31, 2009 (audited)
Warrant Liability			-			6,272			6,272
Additional Paid-in Capital			91,815			2,129			93,944
Accumulated Deficit			-89,975			-8,400			-98,375

Year ended December 31, 2009 (audited)
Change in fair value of warrant liability			-			-10,056			-10,056
Net loss			-2,026			-10,056			-12,082
Net loss per share, basic and diluted			-1.06			-5.26			-6.32

Balance sheet as of January 1, 2009 (audited)
Warrant Liability			-			2,107			2,107
Additional Paid-in Capital			90,375			-3,763			86,612
Accumulated Deficit			-87,949			1,656			-86,293

Historically, the Company had generated net losses thus its basic and diluted earnings per share calculations were based upon the same weighted average shares due to the anti-dilution effect. Certain periods above were restated to reflect net income. As such, the diluted earnings per share calculation for those periods are calculated based upon the treasury stock method as follows:

		(restated)			(restated)			(restated)
		For the three months			For the year			For the six months
		ended September 30,			ended December 31,			ended June 30,
(amounts in 000s, except share and per share data)		2014			2013			2013

Loss per share – Basic:
Numerator for basic income (loss) per share		$	2,723		$	1,322		$	237
Denominator for basic income (loss) per share			25,238,412			15,624,999			14,556,050
Basic income (loss) per common share		$	0.11		$	0.08		$	0.02

Loss per share – Diluted:
Numerator for diluted income (loss) per share		$	2,723		$	1,322			237
Adjust: Fair value of dilutive warrants outstanding			-3,429			-5,020			-2,149
Numerator for diluted income (loss) per share		$	-706			-3,698			-1,912

Denominator for basic income (loss) per share			25,238,412			15,624,999			14,556,050
Plus: Incremental shares underlying warrants outstanding			8,252,777			5,135,411			5,150,160
Denominator for diluted income (loss) per share			33,491,189			20,760,410			19,706,210
Diluted income (loss) per common share		$	-0.02		$	-0.18		$	-0.1

		(restated)			(restated)
		For the three months			For the year
		ended March 31,			ended December 31,
(amounts in 000s, except share and per share data)		2013			2010

Loss per share – Basic:
Numerator for basic income (loss) per share		$	1,514		$	3,880
Denominator for basic income (loss) per share			12,009,285			2,087,068
Basic income (loss) per common share		$	0.13		$	1.86

Loss per share – Diluted:
Numerator for diluted income (loss) per share		$	1,514		$	3,880
Adjust: Fair value of dilutive warrants outstanding			-2,756			-
Numerator for diluted income (loss) per share		$	-1,242		$	3,880

Denominator for basic income (loss) per share			12,009,285			2,087,068
Plus: Incremental shares underlying warrants outstanding			5,624,075			-
Denominator for diluted income (loss) per share			17,633,360			2,087,068
Diluted income (loss) per common share		$	-0.07		$	1.86	-1

(1)The impact of assumed exercise of warrants is not included because all of the warrants outstanding were “out of the money” during this period.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies	Note 3 - Summary of Significant Accounting Policies

	Principles of Consolidation and Basis of Presentation

	The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nephros International Limited. All intercompany accounts and transactions have been eliminated in consolidation.

	Use of Estimates in the Preparation of Financial Statements

	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the valuation of the warrant liability, the collection of accounts receivable, value of inventories, useful life of fixed assets and intangible assets, and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate. Certain prior year amounts have been reclassified to conform to the current year presentation.

	Going Concern and Management’s Response

	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s recurring losses and difficulty in generating sufficient cash flow to meet its obligations and sustain its operations raise substantial doubt about its ability to continue as a going concern. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

	The Company has incurred significant losses from operations in each quarter since inception. In addition, the Company has not generated positive cash flow from operations for the years ended December 31, 2014 and 2013. To become profitable, the Company must increase revenue substantially and achieve and maintain positive gross and operating margins. If the Company is not able to increase revenue and gross and operating margins sufficiently to achieve profitability, its results of operations and financial condition will be materially and adversely affected.

	On December 18, 2014, the Company completed a rights offering which resulted in gross proceeds of $3.0 million. See Note 12, Stockholders’ Deficit, for a more detailed discussion of the rights offering. The Company repaid the August 29, 2014 senior secured note issued to Lambda Investors LLC (“Lambda”) in the principal amount of $1.75 million with a portion of the proceeds from the rights offering. For a more detailed discussion of the terms of the August 2014 senior secured note, see Note 8, Senior Secured Notes.

	There can be no assurance that the Company’s future cash flow will be sufficient to meet its obligations and commitments. If the Company is unable to generate sufficient cash flow from operations in the future to service its commitments, the Company will be required to adopt alternatives, such as seeking to raise debt or equity capital, curtailing its planned activities or ceasing its operations. There can be no assurance that any such actions could be effected on a timely basis or on satisfactory terms or at all, or that these actions would enable the Company to continue to satisfy its capital requirements.

	Concentration of Credit Risk

	The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash.

	Major Customers

	For the years ended December 31, 2014 and 2013, three customers accounted for 78% and 86%, respectively, of the Company’s revenues. As of December 31, 2014 three customers accounted for 83% of the Company’s accounts receivable. As of December 31, 2013, two customers accounted for 97% of the Company’s accounts receivable

	Accounts Receivable

	The Company provides credit terms to customers in connection with purchases of the Company’s products. Management periodically reviews customer account activity in order to assess the adequacy of the allowances provided for potential collection issues and returns. Factors considered include economic conditions, each customer’s payment and return history and credit worthiness. Adjustments, if any, are made to reserve balances following the completion of these reviews to reflect management’s best estimate of potential losses. There was an allowance for doubtful accounts of approximately $1,000 at December 31, 2014. There was no allowance for doubtful accounts at December 31, 2013. There was no allowance for sales returns at December 31, 2014 or 2013. There were no write offs of accounts receivable to bad debt expense during 2014 or 2013.

	Inventory

	The Company engages third parties to manufacture and package inventory held for sale, takes title to certain inventory once manufactured, and warehouses such goods until packaged for final distribution and sale. Inventory consists of finished goods held at the manufacturers’ facilities, and are valued at the lower of cost or market using the first-in, first-out method.

	The Company’s inventory reserve requirements are based on factors including the products’ expiration date and estimates for the future sales of the product. If estimated sales levels do not materialize, the Company will make adjustments to its assumptions for inventory reserve requirements.

	In March 2014, the Company requested the closeout of its October 2013 voluntary product recall. The Company destroyed the respective product in April 2014.

	Patents

	The Company has filed numerous patent applications with the United States Patent and Trademark Office and in foreign countries. All costs and direct expenses incurred in connection with patent applications have been expensed as incurred and are included in Selling, General and Administrative expenses on the accompanying consolidated statement of operations and comprehensive loss.

	Property and Equipment, net

	Property and equipment, net is stated at cost less accumulated depreciation. These assets are depreciated over their estimated useful lives of three to seven years using the straight line method.


	Impairment for Long-Lived Assets

	The Company adheres to Accounting Standards Codification (“ASC”) Topic 360 and periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. An estimate of the asset’s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its carrying value or its estimated net realizable market value. There were no impairment losses for long-lived assets recorded for the years ended December 31, 2014 and December 31, 2013.

	Fair Value of Financial Instruments

	The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturity of these instruments. See Note 4 for information on the fair value of derivative liabilities.

	Revenue Recognition

	Revenue is recognized in accordance with ASC Topic 605. Four basic criteria must be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.

	The Company recognizes revenue related to product sales when delivery is confirmed by its external logistics provider and the other criteria of ASC Topic 605 are met. Product revenue is recorded net of returns and allowances. All costs and duties relating to delivery are absorbed by Nephros. All shipments are currently received directly by the Company’s customers.

	Deferred revenue was approximately $487,000 and $703,000 on the accompanying consolidated balance sheets as of December 31, 2014 and 2013, respectively, and is related to the License Agreement with Bellco. The Company has recognized approximately $2,589,000 of revenue related to this license agreement to date, including approximately $834,000 for the year ended December 31, 2014, resulting in $487,000 being deferred over the remainder of the expected obligation period (see Note 14). The Company recognized approximately $711,000 of revenue related to this license agreement for the year ended December 31, 2013.

Shipping and Handling Costs

Shipping and handling costs charged to customers are recorded as cost of goods sold and were approximately $4,000 and $5,000 for the years ended December 31, 2014 and 2013, respectively.

Research and Development Costs

Research and development costs are expensed as incurred.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC Topic 718 by recognizing the fair value of stock-based compensation in the consolidated statement of operations and comprehensive loss. The fair value of the Company’s stock option awards are estimated using a Black-Scholes option valuation model. This model requires the input of highly subjective assumptions and elections including expected stock price volatility and the estimated life of each award. In addition, the calculation of compensation costs requires that the Company estimate the number of awards that will be forfeited during the vesting period. The fair value of stock-based awards is amortized over the vesting period of the award.

Warrants

The Company accounts for stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Stock warrants that allow for cash settlement or provide for anti-dilution of the warrant exercise price under certain conditions are accounted for as derivative liabilities. The Company classifies derivative warrant liabilities on the balance sheet as a liability, which is revalued using a binomial options pricing model at each balance sheet date subsequent to the initial issuance. A binomial options pricing model requires the input of highly subjective assumptions and elections including expected stock price volatility and the estimated life of each award. The changes in fair value of the derivative warrant liabilities are remeasured at each balance sheet date and the resulting changes in fair value are recorded in current period earnings.

Amortization of Debt Issuance Costs

The Company accounts for debt issuance costs in accordance with ASC 835, which allows that costs paid directly to the issuer of the notes be reported in the balance sheet as a debt discount and amortized over the term of the associated debt. Debt issuance costs associated with the senior secured note issued to Lambda on August 29, 2014 were $178,000. All of these costs, in addition to the remaining unamortized debt issuance costs related to the senior secured note issued to Lambda on November 12, 2013 of $142,000, were amortized as of December 31, 2014 and are included in interest expense on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2014.

Total debt issuance costs recorded during the year ended December 31, 2013 were approximately $399,000. Approximately $195,000 and $204,000, respectively, were associated with the senior secured notes issued to Lambda on February 4, 2013 and November 12, 2013. Of the total debt issuance costs amortized as of December 31, 2013, approximately $53,000 and $204,000, respectively, were related to the senior secured notes issued to Lambda on February 4, 2013 and November 12, 2013 and are included in interest expense on the consolidated statements of operations and comprehensive loss.

Other Income (Expense), net

Other income of approximately $58,000 for the year ended December 31, 2014 is due to foreign currency transaction gains.

Other expense, net, of approximately $33,000 for the year ended December 31, 2013 is primarily due to other expenses of approximately $36,000 related to foreign currency transaction losses and approximately $14,000 related to the May 2013 rights offering warrant modification. These expenses were partially offset by other income of approximately $17,000, which consisted primarily of a refund of $15,000 received as a result of the Steris agreement termination.

Income Taxes

The Company accounts for income taxes in accordance with ASC Topic 740, which requires accounting for deferred income taxes under the asset and liability method. Deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable in future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities.

For financial reporting purposes, the Company has incurred a loss in each period since its inception. Based on available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2014 and 2013.

ASC Topic 740 prescribes, among other things, a recognition threshold and measurement attributes for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company’s income tax return. ASC 740 utilizes a two-step approach for evaluating uncertain tax positions. Step one, or recognition, requires a company to determine if the weight of available evidence indicates a tax position is more likely than not to be sustained upon audit, including resolution of related appeals or litigation processes, if any. Step two, or measurement, is based on the largest amount of benefit, which is more likely than not to be realized on settlement with the taxing authority. The Company is subject to income tax examinations by major taxing authorities for all tax years subsequent to 2011. During the years ended December 31, 2014 and 2013, the Company recognized no adjustments for uncertain tax positions. However, management’s conclusions regarding this policy may be subject to review and adjustment at a later date based on factors including, but not limited to, on-going analyses of and changes to tax laws, regulation and interpretations, thereof.

Net Income (loss) per Common Share

Basic income (loss) per common share is calculated by dividing net income (loss) available to common shareholders by the number of weighted average common shares issued and outstanding. Diluted earnings (loss) per common share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares issued and outstanding for the period, plus amounts representing the dilutive effect from the exercise of stock options and warrants, as applicable. The Company calculates dilutive potential common shares using the treasury stock method, which assumes the Company will use the proceeds from the exercise of stock options and warrants to repurchase shares of common stock to hold in its treasury stock reserves.

The following securities have been excluded from the dilutive per share computation as they are antidilutive:

		December 31,
		2014		2013
Shares underlying options outstanding			2,472,234		2,410,134
Shares underlying warrants outstanding			16,752,915		5,081,023
Unvested restricted stock			132,077		75,450

Foreign Currency Translation

Foreign currency translation is recognized in accordance with ASC Topic 830. The functional currency of Nephros International Limited is the Euro and its translation gains and losses are included in accumulated other comprehensive income. The balance sheet is translated at the year-end rate. The statement of operations is translated at the weighted average rate for the year.

Comprehensive Income (Loss)

Comprehensive income (loss), as defined in ASC 220, is the total of net income (loss) and all other non-owner changes in equity (or other comprehensive income (loss)). The Company’s other comprehensive income (loss) consists only of foreign currency translation adjustments.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, "Revenue from Contracts with Customers," related to revenue recognition. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in prior accounting guidance. ASU 2014-09 provides alternative methods of initial adoption, and it is effective for annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is not permitted. The Company is currently reviewing the revised guidance and assessing the potential impact on its consolidated financial statements.

In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.” ASU 2014-15 provides guidance about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and sets rules for how this information should be disclosed in the financial statements. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating any impact the adoption of ASU 2014-15 might have on its consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-03, “Interest – Imputation of Interest (Subtopic 2015-03): Simplifying the Presentation of Debt Issuance Costs” related to the presentation requirements for debt issuance costs and debt discount and premium. ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by ASU 2015-03. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption of the amendments in ASU 2015-03 is permitted for financial statements that have not been previously issued. The Company does not believe that the adoption of ASU 2015-03 will have a significant impact on its consolidated financial statements.

Financial_Instruments

Financial Instruments	12 Months Ended
Financial Instruments	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures	Note 4 – Financial Instruments

	The Company’s 2007 Warrants are recorded as liabilities at their estimated fair value at the date of issuance, with the subsequent changes in estimated fair value recorded in changes in fair value of warrant liability in the Company’s consolidated statement of operations and comprehensive income (loss) in each subsequent period. The Company utilizes a binomial options pricing model to value the 2007 Warrants.

	The fair value guidance requires fair value measurements be classified and disclosed in one of the following three categories:

		⋅	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

		⋅	Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;

		⋅	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

	The estimated fair value of the 2007 Warrants is determined using Level 3 inputs. Inherent in a binomial options pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock based on historical volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero.

	The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liability measured at fair value on a recurring basis as of December 31, 2014 and 2013 (in thousands).

			Fair value measurement at reporting date using:
			Quoted prices in			Significant other			Significant		Total
			active markets			observable			unobservable
			for			inputs			inputs
			identical assets			(Level 2)			(Level 3)
			(Level 1)
	At December 31, 2014:
	Warrant liability		$	-		$	-		$	7,386	$	7,386

			Fair value measurement at reporting date using:
			Quoted prices in			Significant other			Significant		Total
			active markets			observable			unobservable
			for			inputs			inputs
			identical assets			(Level 2)			(Level 3)
			(Level 1)
	At December 31, 2013:
	Warrant liability		$	-		$	-		$	3,109	$	3,109

	The Company has issued warrants to purchase common stock that are measured at fair value on a recurring basis using unobservable inputs or available market data in a binomial options pricing model to support the fair value (Level 3). A reconciliation of the warrant liability is as follows (in thousands):

			2007 Warrants
	Balance at January 1, 2013		$	8,129
	Decrease in fair value of warrant liability			-5,020
	Balance at December 31, 2013		$	3,109
	Increase in fair value of warrant liability			4,277
	Balance at December 31, 2014		$	7,386

	The following table summarizes the calculated aggregate fair values of the warrants, along with the assumptions utilized in each calculation:

			2014				2013
	Calculated aggregate value		$	7,386			$	3,109
	Weighted average exercise price		$	0.3			$	0.4
	Closing price per share of common stock		$	0.79			$	0.42
	Volatility			165.6	%			103.5	%
	Weighted average remaining expected life (years)			5.2				5
	Risk-free interest rate			1.8	%			1.6	%
	Dividend yield			-				-

Inventory

Inventory	12 Months Ended
Inventory	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory	Note 5 - Inventory

	The Company’s inventory components as of December 31, 2014 and 2013 were as follows:

		December 31,
		2014		2013
	Total gross inventory, finished goods	$	297,000	$	527,000
	Less: inventory reserve		-111,000		-365,000
	Total inventory	$	186,000	$	162,000

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	12 Months Ended
Prepaid Expenses and Other Current Assets	Dec. 31, 2014
Other Assets [Abstract]
Prepaid Expenses and Other Current Assets	Note 6 - Prepaid Expenses and Other Current Assets

	Prepaid expenses and other current assets as of December 31, 2014 and 2013 were as follows:

		December 31,
		2014		2013
	Prepaid insurance premiums	$	70,000	$	70,000
	Security deposit		21,000		21,000
	Other		13,000		34,000
	Prepaid expenses and other current assets	$	104,000	$	125,000

Property_and_Equipment_Net

Property and Equipment, Net	12 Months Ended
Property and Equipment, Net	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Note 7 - Property and Equipment, Net

	Property and equipment as of December 31, 2014 and 2013 was as follows:

			December 31,
		Life	2014		2013
	Manufacturing equipment	3-5 years	$	599,000	$	599,000
	Research equipment	5 years		37,000		37,000
	Computer equipment	3-4 years		59,000		59,000
	Furniture and fixtures	7 years		39,000		39,000
	Property and equipment, gross			734,000		734,000
	Less: accumulated depreciation			733,000		727,000
	Property and equipment, net		$	1,000	$	7,000

	Depreciation expense for each of the years ended December 31, 2014 and 2013 was approximately $6,000 and $9,000, respectively.

	During 2013, the Company sold fully depreciated equipment totaling approximately $3,000 which is reflected as gain on sale of equipment on the consolidated statements of operations and comprehensive loss.

Senior_Secured_Notes

Senior Secured Notes	12 Months Ended
Senior Secured Notes	Dec. 31, 2014
Debt Disclosure [Abstract]
Senior Secured Notes	Note 8 – Senior Secured Notes

	On August 29, 2014, the Company issued a senior secured note to Lambda, in the principal amount of $1.75 million. The note bore interest at the rate of 12% per annum and was scheduled to mature on February 28, 2015, at which time all principal and accrued interest was due. However, the Company paid all amounts due under the note on December 18, 2014 with the cash proceeds from the rights offering that closed in December 2014. In connection with the note, the Company incurred an 8%, or $140,000, sourcing/transaction fee with Lambda. In addition, the Company incurred additional legal fees and other expenses in connection with the note in the amount of $38,000 with Lambda. Those payments totaling $178,000 were initially reflected as a debt discount and amortized over the term of the note. For the year ended December 31, 2014, $178,000 is included in interest expense on the consolidated statements of operations and comprehensive loss.

	On November 12, 2013, the Company issued a senior secured note to Lambda in the principal amount of $1.5 million. The note bore interest at the rate of 12% per annum and was scheduled to mature on May 12, 2014, at which time all principal and accrued interest was due. However, the Company paid amounts due under the note on March 18, 2014 with the cash proceeds from the rights offering that closed in March 2014. In connection with the note, the Company incurred an 8%, or $120,000, sourcing/transaction fee with Lambda. In addition, the Company incurred additional legal fees and other expenses in connection with the note in the amount of $75,000 with Lambda. Those payments totaling $195,000 were made on November 12, 2013 and are reflected as a debt discount which was amortized over the term of the senior secured note. Approximately $142,000 and $53,000, respectively, are included in interest expense on the consolidated statements of operations and comprehensive loss for the years ended December 31, 2014 and 2013.

	Lambda is an affiliate of Wexford Capital LP, which is the managing member of Lambda. Arthur H. Amron, a director of the Company, is a partner and general counsel of Wexford Capital LP. Paul A. Mieyal, a director of the Company and currently its acting President, CEO and CFO, is also a Vice President of Wexford Capital LP.

Accrued_Expenses

Accrued Expenses	12 Months Ended
Accrued Expenses	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Expenses	Note 9 - Accrued Expenses

	Accrued expenses as of December 31, 2014 and 2013 were as follows:

		December 31,
		2014		2013
	Accrued legal	$	145,000	$	149,000
	Accrued management bonus		50,000		81,000
	Accrued directors’ compensation		36,000		-
	Accrued stock transfer agent fees		27,000		-
	Accrued accounting		23,000		-
	Accrued interest		14,000		39,000
	Accrued product recall		-		60,000
	Accrued other		47,000		36,000
		$	342,000	$	365,000

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Note 10 - Income Taxes

	A reconciliation of the income tax provision computed at the statutory tax rate to the Company’s effective tax rate is as follows:

		2014		2013
	U.S. federal statutory rate	35	%	35	%
	Warrant liability	-23.7	%	-155.1	%
	State & local taxes	5.02	%	6.4	%
	Tax on foreign operations	0.2	%	2	%
	State research and development credits	0.55	%	-3.1	%
	Other	-3.1	%	6.5	%
	Valuation allowance	-13.97	%	108.3	%
	Effective tax rate	-		-

	Significant components of the Company’s deferred tax assets as of December 31, 2014 and 2013 are as follows:

		2014		2013
	Deferred tax assets:
	Net operating loss carry forwards	$	27,935,165	$	27,029,000
	Research and development credits		1,118,389		1,096,000
	Nonqualified stock option compensation expense		1,913,673		1,801,000
	Other temporary book - tax differences		436,178		408,000
	Total deferred tax assets		31,403,405		30,334,000
	Valuation allowance for deferred tax assets		-31,403,405		-30,334,000
	Net deferred tax assets	$	-	$	-

	A valuation allowance has been recognized to offset the Company’s net deferred tax asset as it is more likely than not that such net asset will not be realized. The Company primarily considered its historical loss and potential Internal Revenue Code Section 382 limitations to arrive at its conclusion that a valuation allowance was required.

	At December 31, 2014, the Company had Federal and New Jersey income tax net operating loss carryforwards of $92,928,000 and foreign income tax net operating loss carryforwards of $8,070,000. The Company also had Federal research tax credit carryforwards of $1,118,389 at December 31, 2014 and $1,096,000 at December 31, 2013. The Federal and New Jersey net operating loss carryforwards and Federal tax credit carryforwards will expire at various times between 2014 and 2026 unless utilized.

	It is the Company’s policy to report interest and penalties, if any, related to unrecognized tax benefits in income tax expense.

Stock_Plans_ShareBased_Payment

Stock Plans, Share-Based Payments and Warrants	12 Months Ended
Stock Plans, Share-Based Payments and Warrants	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Plans, Share-Based Payments and Warrants	Note 11 - Stock Plans, Share-Based Payments and Warrants

	Stock Plans

	In 2000, the Company adopted the Nephros 2000 Equity Incentive Plan. In January 2003, the Board of Directors adopted an amendment and restatement of the plan and renamed it the Amended and Restated Nephros 2000 Equity Incentive Plan (the “2000 Plan”), under which 106,538 shares of common stock had been authorized for issuance upon exercise of options granted.

	As of December 31, 2014 there were no outstanding options under the 2000 Plan. On March 15, 2014, the 2,834 options outstanding as of December 31, 2013 expired.

	The Board retired the 2000 Plan in June 2004, and thereafter no additional awards may be granted under the 2000 Plan.

	In 2004, the Board of Directors adopted and the Company’s stockholders approved the Nephros, Inc. 2004 Stock Incentive Plan. During the year ended December 31, 2013, the Company’s stockholders approved an amendment to such plan (as amended, the “2004 Plan”), that increased the number of shares of the Company’s common stock that are authorized for issuance by the Company pursuant to grants of awards under the 2004 Plan to 4,500,000.

	As of December 31, 2014, 1,236,975 options had been issued to employees under the 2004 Plan and were outstanding. The options expire on various dates between April 27, 2015 and February 5, 2024, and have vested or will vest upon a combination of the following: immediate vesting or straight line vesting of two or four years. At December 31, 2014, there were 2,054,799 shares available for future grants under the 2004 Plan. As of December 31, 2014, 903,709 options had been issued to non-employees under the 2004 Plan and were outstanding. Such options expire at various dates between April 26, 2015 and November 17, 2024, and vest upon a combination of the following: immediate vesting or straight line vesting of two or four years.

	As of December 31, 2013, 1,028,509 options had been issued to employees under the 2004 Plan and were outstanding. The options expire on various dates between April 27, 2015 and March 24, 2021, and vest upon a combination of the following: immediate vesting or straight line vesting of two or four years. At December 31, 2013, there were 2,407,318 shares available for future grants under the 2004 Plan. As of December 31, 2013, 715,692 options had been issued to non-employees under the 2004 Plan and were outstanding. Such options expire at various dates between November 11, 2014 and November 18, 2021, and vest upon a combination of the following: immediate vesting or straight line vesting of two or four years.

	In addition, 331,550 options were issued in 2012 to the Company’s CEO per terms of his employment agreement and were outstanding as of December 31, 2014 and 2013.

	Share-Based Payment

	Expense is recognized, net of expected forfeitures, over the vesting period of the options. Stock based compensation expense recognized for the years ended December 31, 2014 and 2013 was approximately $421,000 and approximately $418,000, respectively.

	Gerald J. Kochanski, Chief Financial Officer, Treasurer and Corporate Secretary of Nephros, Inc., resigned effective June 15, 2013. The Company agreed, in consideration of Mr. Kochanski providing certain consulting services to the Company, to extend the exercise period of his outstanding vested stock options from September 15, 2013 to March 14, 2014. The change in the terms under this modification did not result in any additional compensation expense. All of Mr. Kochanski’s vested stock options expired on March 14, 2014.

	The following table summarizes the option activity for the years ended December 31, 2014 and 2013:

			Shares		Weighted
					Average
					Exercise
					Price
	Outstanding at December 31, 2012		2,294,714		$	2.14
	Options granted		237,315			0.64
	Options forfeited or expired		-121,895			3.27
	Outstanding at December 31, 2013		2,410,134			1.28
	Options granted		352,519			0.5
	Options forfeited or expired		-290,419			2.45
	Outstanding at December 31, 2014		2,472,234		$	0.96

	The following table summarizes the options exercisable and vested and expected to vest as of December 31, 2014 and 2013:

			Shares		Weighted
					Average
					Exercise
					Price
	Exercisable at December 31, 2013		1,385,199		$	1.46
	Vested and expected to vest at December 31, 2013		2,350,688		$	1.29
	Exercisable at December 31, 2014		1,679,392		$	1.11
	Vested and expected to vest at December 31, 2014		2,426,249		$	1.04

	The following table summarizes information about stock options outstanding and exercisable at December 31, 2014:

			Options Outstanding							Options Exercisable
	Range of Exercise		Number		Weighted		Weighted			Number	Weighted
	Price		Outstanding as		Average		Average			Exercisable as	Average
			of December		Remaining		Exercise			of	Exercise Price
			31, 2014		Contractual		Price			December 31,
					Life in					2014
					Years

	$0.33 - $2.60		2,460,284		8.57		$	0.91		1,667,441	$	0.92
	$15.40 - $29.80		10,450		4.51		$	21.89		10,450	$	21.89
	$51.40-$96.00		1,500		1.58		$	64.47		1,500	$	64.47

	Total Outstanding		2,472,234				$	0.96		1,679,392	$	1.11

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the below assumptions for the risk-free interest rates, expected dividend yield, expected lives and expected stock price volatility.

		Option Pricing Assumptions
Grant Year		2014		2013
Stock Price Volatility		129.8	%	129.8	%
Risk-Free Interest Rates		1.86	%	1.36	%
Expected Life (in years)		5.84		5.91
Expected Dividend Yield		0	%	0	%

Expected volatility is based on historical volatility of the Company’s common stock at the time of grant. The risk-free interest rate is based on the U.S. Treasury yields in effect at the time of grant for periods corresponding with the expected life of the options. For the expected life, the Company is using the simplified method as described in the SEC Staff Accounting Bulletin 107. This method assumes that stock option grants will be exercised based on the average of the vesting periods and the option’s life.

The total fair value of options vested during the fiscal year ended December 31, 2014 was approximately $507,000. The total fair value of options vested during the fiscal year ended December 31, 2013 was approximately $519,000.

The weighted-average fair value of options granted in 2014 and 2013 is $0.45 and $0.56, respectively. The aggregate intrinsic value of stock options outstanding at December 31, 2014 is $241,000 and of stock options vested or expected to vest is approximately $235,000. A stock option has intrinsic value, at any given time, if and to the extent that the exercise price of such stock option is less than the market price of the underlying common stock at such time. The weighted-average remaining contractual life of options vested or expected to vest is 7.5 years.

The aggregate intrinsic value of stock options outstanding at December 31, 2013 is $0 and of stock options vested or expected to vest is approximately $0. A stock option has intrinsic value, at any given time, if and to the extent that the exercise price of such stock option is less than the market price of the underlying common stock at such time. The weighted-average remaining contractual life of options vested or expected to vest is 8.1 years.

As of December 31, 2014, the total remaining unrecognized compensation cost related to non-vested stock options amounted to $504,000 and will be amortized over the weighted-average remaining requisite service period of 1.9 years.


Restricted Stock

The Company has issued restricted stock as compensation for the services of certain employees and non-employee directors. The grant date fair value of restricted stock was based on the fair value of the common stock on the date of grant, and compensation expense is recognized based on the period in which the restrictions lapse.

The following table summarizes restricted stock activity for the year end December 31, 2014 and 2013:

					Weighted
					Average
					Grant Date
		Shares			Fair Value
Nonvested at December 31, 2012			-		$	-
Granted			398,227			0.73
Vested			-264,770			0.71
Forfeited			-58,007			0.88
Nonvested at December 31, 2013			75,450			0.66
Granted			132,077			0.86
Vested			-75,450			0.66
Nonvested at December 31, 2014			132,077		$	0.86

Total stock-based compensation expense for the restricted stock was approximately $109,000 for the year ended December 31, 2014 and is included in Selling, General and Administrative expenses on the accompanying consolidated statement of operations and comprehensive loss. Any additional stock-based compensation related to non-employee directors will be recorded to stock-based compensation expense. As of December 31, 2014, there was approximately $8,000 of unrecognized compensation expense related to the restricted stock awards, which is expected to be recognized over the next four months.

Warrants

The Company accounts for stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Stock warrants are accounted for as derivative liabilities if the stock warrants allow for cash settlement or provide for modification of the warrant exercise price in the event that subsequent sales of common stock are at a lower price per share than the then-current warrant exercise price. The Company classifies derivative warrant liabilities on the balance sheet as a long-term liability, which is measured to fair value at each balance sheet date subsequent to the initial issuance of the stock warrant.

The following table summarizes certain terms of all of the Company’s outstanding warrants at December 31, 2014 and 2013:

		Total Outstanding Warrants
									Total Common
Title of Warrant		Date Issued		Expiry Date		Exercise Price			Shares Issuable as December 31,
									2014		2013
Liability-classified warrants
2007 Warrants - Lambda		11/14/07		3/21/19		$	0.3			11,742,100		8,806,575
										11,742,100		8,806,575

Equity-classified warrants
July 2009 Warrants		7/24/09		7/24/14		$	22.4			-		33,629
Shareholder Rights Offering Warrants		3/10/11		3/10/16		$	0.4			2,228,238		2,264,817
March 2011 Lambda Warrants		3/10/11		3/21/19		$	0.4			2,782,577		2,782,577
										5,010,815		5,081,023
Total										16,752,915		13,887,598

The weighted average exercise price of the outstanding warrants was $0.33 for December 31, 2014 and $0.45 for December 2013.

Following the issuance of the August 2014 senior secured note, Lambda’s existing warrants to purchase 11,742,100 shares that remain outstanding were amended to expire on March 21, 2019.

As a result of the March 2014 rights offering, the full ratchet anti-dilution protection for Class D warrants held by Lambda was triggered. The respective warrants are now exercisable for 11,742,100 shares of common stock at an exercise price of $0.30 per share compared to the 8,806,575 shares of common stock and $0.40 exercise price prior to the rights offering.

Warrants exercised during 2014 and 2013

During the twelve months ended December 31, 2014, 791,278 warrants were exercised, resulting in proceeds of approximately $15,000 and the issuance of 36,570 shares of the Company’s common stock.

In connection with the May 2013 rights offering, the Company temporarily reduced the exercise price for its warrants issued in March 2011 from $0.40 per share to $0.30 per share. The Company determined that this inducement was a modification of equity instruments and, therefore, an incremental fair value of the inducement was determined using the Black-Scholes option pricing model.

During the period that the May 2013 rights offering was open, warrant holders exercised 14,879,708 warrants, issued in March 2011, for 687,793 shares of common stock, resulting in gross proceeds of approximately $206,000 to the Company. The incremental fair value of the inducement recorded in the year ended December 31, 2013 was approximately $14,000.

Additionally, during the twelve months ended December 31, 2013, 2,254,500 warrants were exercised outside the period that the May 2013 rights offering was open, resulting in proceeds of approximately $42,000 and the issuance of 104,206 shares of the Company’s common stock.

In addition, 9 and 374 common shares, respectively, were not issued as a result of warrant exercises for the years ended December 31, 2014 and 2013 due to rounding.

Stockholders_Deficit

Stockholders' Deficit	12 Months Ended
Stockholders' Deficit	Dec. 31, 2014
Comprehensive Income (Loss) [Abstract]
Stockholdersb Deficit	Note 12 – Stockholders’ Deficit

	December 2014 Rights Offering

	On October 20, 2014, the Company filed a Registration Statement on Form S-1 in connection with a $3 million rights offering. On November 4, 2014, the Company’s Registration Statement on Form S-1 related to the Rights Offering was declared effective by the SEC.

	The December 2014 rights offering commenced on November 10, 2014 and expired on December 15, 2014. All of the Company’s stockholders and warrant holders were eligible to participate in the rights offering on a pro rata basis based upon their proportionate ownership of the Company’s common stock on a fully-diluted basis. Pursuant to the rights offering, the Company distributed to holders of its common stock and/or warrants one non-transferable subscription right for each share of common stock, and each share of common stock underlying a warrant, held as of November 5, 2014. Each right entitled the holder to purchase 0.11901 of a share of the Company’s common stock at a subscription price of $0.60 per share. The Company rounded up any fractional shares to the nearest whole share.

	On December 18, 2014, the Company completed a rights offering which resulted in the issuance of 5,000,000 shares for gross proceeds of $3.0 million. The aggregate net proceeds were approximately $1.1 million, after deducting the repayment of the $1.75 million August 2014 senior secured note, plus $64,000 of accrued interest thereon, issued to Lambda, and an aggregate of $75,000 for reimbursement of Lambda’s legal fees incurred in connection with the August 2014 senior secured note and the rights offering.

	March 2014 Rights Offering

	On January 7, 2014, the Company filed a Registration Statement on Form S-1 in connection with a $2.8 million rights offering. On February 12, 2014, the Company’s Registration Statement on Form S-1 related to the March 2014 rights offering was declared effective by the SEC. The March 2014 rights offering commenced on February 14, 2014 and expired on March 14, 2014. All of the Company’s stockholders and warrant holders were eligible to participate in the March 2014 rights offering on a pro rata basis based upon their proportionate ownership of the Company’s common stock on a fully-diluted basis. Pursuant to the March 2014 rights offering, the Company distributed to holders of its common stock and/or warrants one non-transferable subscription right for each share of common stock, and each share of common stock underlying a warrant, held as of January 30, 2014. Each right entitled the holder to purchase 0.28673 of a share of the Company’s common stock at a subscription price of $0.30 per share. The Company rounded up any fractional shares to the nearest whole share.

	On March 21, 2014, the Company completed the March 2014 rights offering that resulted in gross proceeds of $2.1 million. The aggregate net proceeds were approximately $581,000, after deducting the repayment of the November 2013 $1.5 million senior secured note and the $61,000 of accrued interest thereon.

	The Company issued a total of 7,140,823 shares of common stock to the holders of subscription rights who validly exercised their subscription rights, which represents 77% of the total shares offered in the March 2014 rights offering. Fees of approximately $128,000 were also incurred related to the March 2014 rights offering and were recorded as reduction to equity.

	May 2013 Rights Offering

	On March 4, 2013, the Company filed a Registration Statement on Form S-1 in connection with a $3 million rights offering. On April 17, 2013, the Company’s Registration Statement on Form S-1 related to the May 2013 rights offering was declared effective by the SEC.

	The May 2013 rights offering commenced on April 17, 2013 and expired on May 17, 2013. All of the Company’s stockholders and warrant holders were eligible to participate in the Rights Offering on a pro rata basis based upon their proportionate ownership of the Company’s common stock on a fully-diluted basis. Pursuant to the May 2013 rights offering, the Company distributed to holders of its common stock and/or warrants one non-transferable subscription right for each share of common stock, and each share of common stock underlying a warrant, held as of April 4, 2013. Each right entitled the holder to purchase 0.18776 of a share of the Company’s common stock at a subscription price of $0.60 per share. The Company rounded up any fractional shares to the nearest whole share.

	On May 22, 2013, the Company completed its May 2013 rights offering which resulted in the issuance of 5,000,000 shares for gross proceeds of $3.0 million. The aggregate net proceeds were approximately $1.4 million, after deducting the repayment of the $1.3 million February 2013 senior secured note, plus $46,800 of accrued interest thereon, issued to Lambda, the payment of an 8% sourcing transaction fee of $104,000 with respect to the February 2013 senior secured note and an aggregate of $100,000 for reimbursement of Lambda’s legal fees incurred in connection with the February 2013 senior secured note and the May 2013 rights offering. Those payments totaling $204,000 are reflected as amortization of debt discount.

401k_Plan

401(k) Plan	12 Months Ended
401(k) Plan	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
401(k) Plan	Note 13 - 401(k) Plan

	The Company has established a 401(k) deferred contribution retirement plan (the “401(k) Plan”) which covers all employees. The 401(k) Plan provides for voluntary employee contributions of up to 15% of annual earnings, as defined. As of January 1, 2004, the Company matches 100% of the first 3% and 50% of the next 2% of employee contributions to the 401(k) Plan. The Company contributed and expensed $43,000 and $46,000 in 2014 and 2013, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14 - Commitments and Contingencies

	Manufacturing and Suppliers

	The Company has not and does not intend in the near future, to manufacture any of its products and components. With regard to the OLpur MD190 and MD220, on June 27, 2011, the Company entered into a license agreement, effective July 1, 2011, with Bellco S.r.l., an Italy-based supplier of hemodialysis and intensive care products, for the manufacturing, marketing and sale of our patented mid-dilution dialysis filters (MD 190, MD 220), referred to herein as the Products. Under the agreement, Nephros granted Bellco a license to manufacture, market and sell the Products under its own name, label and CE mark in Italy, France, Belgium, Spain and Canada on an exclusive basis, and to do the same on a non-exclusive basis in the United Kingdom and Greece and, upon our written approval, other European countries where the Company does not sell the Products as well as non-European countries (referred to as the “Territory”).

	On February 19, 2014, the Company entered into the First Amendment to License Agreement (the “First Amendment”), by and between the Company and Bellco, which amends the License Agreement, entered into as of July 1, 2011 by and between the Company and Bellco. Pursuant to the First Amendment, the Company and Bellco agreed to extend the term of the License Agreement from December 31, 2016 to December 31, 2021. The First Amendment also expands the Territory covered by the License Agreement to include Sweden, Denmark, Norway, Finland, Korea, Mexico, Brazil, China and the Netherlands. The First Amendment further provides new minimum sales targets which, if not satisfied, will, at the discretion of the Company, result in conversion of the license to non-exclusive status. The Company has agreed to reduce the fixed royalty payment payable to the Company for the period beginning on January 1, 2015 through and including December 31, 2021. Beginning on January 1, 2015 through and including December 31, 2021, Bellco will pay the Company a royalty based on the number of units of Products sold per year in the Territory as follows: for the first 125,000 units sold in total, €1.75 (approximately $2.40) per unit; thereafter, €1.25 (approximately $1.71) per unit. In addition, the Company received a total of €450,000 (approximately $612,000) in upfront fees in connection with the First Amendment, half of which was received on February 19, 2014 and the remaining half was received on April 4, 2014. In addition, the First Amendment provides that, in the event that the Company pursues a transaction to sell, assign or transfer all right, title and interest to the licensed patents to a third party, the Company will provide Bellco with written notice thereof and a right of first offer with respect to the contemplated transaction for a period of thirty (30) days.

	License and Supply Agreement

	On April 23, 2012, the Company entered into a License and Supply Agreement (the “License and Supply Agreement”) with Medica S.p.A. (“Medica”), an Italy-based medical product manufacturing company, for the marketing and sale of certain filtration products based upon Medica’s proprietary Medisulfone ultrafiltration technology in conjunction with the Company’s filtration products (collectively, the “Filtration Products”), and to engage in an exclusive supply arrangement for the Filtration Products. Under the License and Supply Agreement, Medica granted to the Company an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale and sell the Filtration Products worldwide, excluding Italy for the first three years, during the term of the License and Supply Agreement. In addition, the Company granted to Medica an exclusive license under the Company’s intellectual property to make the Filtration Products during the term of the License and Supply Agreement. In exchange for the rights granted, the Company agreed to make minimum annual aggregate purchases from Medica of €300,000 (approximately $400,000), €500,000 (approximately $700,000) and €750,000 (approximately $880,000) for the years 2012, 2013 and 2014, respectively. In the year ended December 31, 2014, the Company’s aggregate purchase commitments totaled approximately €766,000 (approximately $900,000). For calendar years 2015 through 2022, annual minimum amounts will be mutually agreed upon between Medica and the Company. The annual minimum amount for calendar 2015 has not been finalized. In exchange for the license, the Company paid Medica a total of €1,500,000 (approximately $2,000,000) in three installments: €500,000 (approximately $700,000) on April 23, 2012, €600,000 (approximately $800,000) on February 4, 2013, and €400,000 (approximately $500,000) on May 23, 2013.

	As further consideration for the license and other rights granted to the Company, the Company granted Medica options to purchase 300,000 shares of the Company’s common stock. The fair market value of these stock options was approximately $273,000 at the time of their issuance, calculated as described in Note 2 under Stock-Based Compensation. The fair market value of the options has been capitalized as a long-term intangible asset along with the total installment payments described. Other long-term assets on the consolidated balance sheet is approximately $1,684,000, net of $566,000 accumulated amortization, and is related to the License and Supply Agreement. The asset is being amortized as an expense over the life of the agreement. Approximately $210,000 and $214,000 have been charged to amortization expense for the years ended December 31, 2014 and 2013, respectively, on the consolidated statement of operations and comprehensive loss. Approximately $210,000 of amortization expense will be recognized in each of the years ended December 31, 2015 through 2022. In addition, for the period beginning April 23, 2014 through December 31, 2022, the Company will pay Medica a royalty rate of 3% of net sales of the Filtration Products sold, subject to reduction as a result of a supply interruption pursuant to the terms of the License and Supply Agreement. The term of the License and Supply Agreement commenced on April 23, 2012 and continues in effect through December 31, 2022, unless earlier terminated by either party in accordance with the terms of the License and Supply Agreement.

	The Company has an understanding with Medica whereby the Company has agreed to pay interest to Medica at a 12% annual rate calculated on the principal amount of any outstanding invoices that are not paid pursuant to the original payment terms.

	Contractual Obligations

	The Company had an operating lease that expired on November 30, 2014 for the rental of its U.S. office and research and development facilities with a monthly cost of approximately $8,000. On August 27, 2014, the Company signed a one year lease extension for the same office space which will expire on November 30, 2015 with a monthly cost of approximately $8,800 beginning December 1, 2014.

	The lease agreement for the facilities in Europe was entered into on July 1, 2010. The lease term is renewable for 6 month terms with a 2 month notice to discontinue, on a rolling basis. The monthly cost is 500 Euro (approximately $600).

	Rent expense for the years ended December 31, 2014 and 2013 totaled $117,000 and $116,000, respectively.

	Contractual Obligations and Commercial Commitments

	The following tables summarize our approximate minimum contractual obligations and commercial commitments as of December 31, 2014:

		Payments Due in Period
				Within		Years		Years		More than
		Total		1 Year		1 - 3		4 - 5		5 Years

	Leases	$	106,000	$	104,000	$	2,000	$	-	$	-
	Employment Contracts (1)		175,000		175,000		-		-		-
	Total	$	281,000	$	279,000	$	2,000	$	-	$	-

	(1) Represents amount payable under severance agreement for John C. Houghton, effective January 4, 2015. See Note 15, Subsequent Events, for further discussion.

	Product Recall

	On October 30, 2013, the Company filed a Current Report on Form 8-K announcing the voluntary recalls of its point of use (POU) and DSU in-line ultrafilters used in hospital water treatment applications. As a result, the Company recalled all production lots of its POU filters, and also requested that customers remove and discard certain labeling/promotional materials for the products. In addition, the Company also requested, for the DSU in-line ultrafilter, that customers remove and discard certain labeling/promotional materials for the product. These voluntary recalls did not affect the Company’s dialysis products. The consolidated financial statements for the year ended December 31, 2013 included product revenues and cost of goods sold adjustments of approximately $216,000 and $110,000, respectively, reflecting estimates of the financial impact of product recalled to the Company. The recall and the related circumstances could subject the Company to claims or proceedings by consumers, the FDA or other regulatory authorities which may adversely impact the Company’s sales and revenues. The Company destroyed the respective product in April 2014.

Subsequent_Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Note 15 - Subsequent Events

	On January 4, 2015, the Board of Directors appointed Daron Evans, a member of the Board, to serve as Chairman of the Board. Also on January 4, 2015, the Board of Directors appointed Paul A. Mieyal, a member of the Board, to serve as the Acting President, Acting Chief Executive Officer, Acting Chief Financial Officer and Acting Secretary of the Company. Dr. Mieyal succeeded John C. Houghton, whose separation of employment as President, Chief Executive Officer and Acting Chief Financial Officer of the Company was effective on January 4, 2015. In addition, Mr. Houghton resigned as a member of the Board, effective on January 4, 2015. The resignation as a member of the Board was not due to any disagreement by or with Mr. Houghton on any matter relating to the Company’s operations, policies or practices. In connection with his separation from employment with the Company, Mr. Houghton entered into a Separation Agreement and General Release (the “Agreement”). Pursuant to the Agreement, Mr. Houghton is entitled to six months severance and is permitted to exercise his vested unexpired stock options for ninety days following January 4, 2015. During the severance term, Mr. Houghton will be subject to customary non-competition, non-solicitation and confidentiality restrictions.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation

	The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nephros International Limited. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements

	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the valuation of the warrant liability, the collection of accounts receivable, value of inventories, useful life of fixed assets and intangible assets, and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate. Certain prior year amounts have been reclassified to conform to the current year presentation.

Going Concern and Management's Response	Going Concern and Management’s Response

	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s recurring losses and difficulty in generating sufficient cash flow to meet its obligations and sustain its operations raise substantial doubt about its ability to continue as a going concern. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

	The Company has incurred significant losses from operations in each quarter since inception. In addition, the Company has not generated positive cash flow from operations for the years ended December 31, 2014 and 2013. To become profitable, the Company must increase revenue substantially and achieve and maintain positive gross and operating margins. If the Company is not able to increase revenue and gross and operating margins sufficiently to achieve profitability, its results of operations and financial condition will be materially and adversely affected.

	On December 18, 2014, the Company completed a rights offering which resulted in gross proceeds of $3.0 million. See Note 12, Stockholders’ Deficit, for a more detailed discussion of the rights offering. The Company repaid the August 29, 2014 senior secured note issued to Lambda Investors LLC (“Lambda”) in the principal amount of $1.75 million with a portion of the proceeds from the rights offering. For a more detailed discussion of the terms of the August 2014 senior secured note, see Note 8, Senior Secured Notes.

	There can be no assurance that the Company’s future cash flow will be sufficient to meet its obligations and commitments. If the Company is unable to generate sufficient cash flow from operations in the future to service its commitments, the Company will be required to adopt alternatives, such as seeking to raise debt or equity capital, curtailing its planned activities or ceasing its operations. There can be no assurance that any such actions could be effected on a timely basis or on satisfactory terms or at all, or that these actions would enable the Company to continue to satisfy its capital requirements.

Concentration of Credit Risk	Concentration of Credit Risk

	The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash.

Major Customers	Major Customers

	For the years ended December 31, 2014 and 2013, three customers accounted for 78% and 86%, respectively, of the Company’s revenues. As of December 31, 2014 three customers accounted for 83% of the Company’s accounts receivable. As of December 31, 2013, two customers accounted for 97% of the Company’s accounts receivable

Accounts Receivable	Accounts Receivable

	The Company provides credit terms to customers in connection with purchases of the Company’s products. Management periodically reviews customer account activity in order to assess the adequacy of the allowances provided for potential collection issues and returns. Factors considered include economic conditions, each customer’s payment and return history and credit worthiness. Adjustments, if any, are made to reserve balances following the completion of these reviews to reflect management’s best estimate of potential losses. There was an allowance for doubtful accounts of approximately $1,000 at December 31, 2014. There was no allowance for doubtful accounts at December 31, 2013. There was no allowance for sales returns at December 31, 2014 or 2013. There were no write offs of accounts receivable to bad debt expense during 2014 or 2013.

Inventory	Inventory

	The Company engages third parties to manufacture and package inventory held for sale, takes title to certain inventory once manufactured, and warehouses such goods until packaged for final distribution and sale. Inventory consists of finished goods held at the manufacturers’ facilities, and are valued at the lower of cost or market using the first-in, first-out method.

	The Company’s inventory reserve requirements are based on factors including the products’ expiration date and estimates for the future sales of the product. If estimated sales levels do not materialize, the Company will make adjustments to its assumptions for inventory reserve requirements.

	In March 2014, the Company requested the closeout of its October 2013 voluntary product recall. The Company destroyed the respective product in April 2014.

Patents	Patents

	The Company has filed numerous patent applications with the United States Patent and Trademark Office and in foreign countries. All costs and direct expenses incurred in connection with patent applications have been expensed as incurred and are included in Selling, General and Administrative expenses on the accompanying consolidated statement of operations and comprehensive loss.

Property and Equipment, net	Property and Equipment, net

	Property and equipment, net is stated at cost less accumulated depreciation. These assets are depreciated over their estimated useful lives of three to seven years using the straight line method.

Impairment for Long-Lived Assets	Impairment for Long-Lived Assets

	The Company adheres to Accounting Standards Codification (“ASC”) Topic 360 and periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. An estimate of the asset’s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its carrying value or its estimated net realizable market value. There were no impairment losses for long-lived assets recorded for the years ended December 31, 2014 and December 31, 2013.

Fair Value of Financial Instruments	Fair Value of Financial Instruments

	The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturity of these instruments. See Note 4 for information on the fair value of derivative liabilities.

Revenue Recognition	Revenue Recognition

	Revenue is recognized in accordance with ASC Topic 605. Four basic criteria must be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.

	The Company recognizes revenue related to product sales when delivery is confirmed by its external logistics provider and the other criteria of ASC Topic 605 are met. Product revenue is recorded net of returns and allowances. All costs and duties relating to delivery are absorbed by Nephros. All shipments are currently received directly by the Company’s customers.

	Deferred revenue was approximately $487,000 and $703,000 on the accompanying consolidated balance sheets as of December 31, 2014 and 2013, respectively, and is related to the License Agreement with Bellco. The Company has recognized approximately $2,589,000 of revenue related to this license agreement to date, including approximately $834,000 for the year ended December 31, 2014, resulting in $487,000 being deferred over the remainder of the expected obligation period (see Note 14). The Company recognized approximately $711,000 of revenue related to this license agreement for the year ended December 31, 2013.

Shipping and Handling Costs	Shipping and Handling Costs

	Shipping and handling costs charged to customers are recorded as cost of goods sold and were approximately $4,000 and $5,000 for the years ended December 31, 2014 and 2013, respectively.

Research and Development Costs	Research and Development Costs

	Research and development costs are expensed as incurred.

Stock-Based Compensation	Stock-Based Compensation

	The Company accounts for stock-based compensation in accordance with ASC Topic 718 by recognizing the fair value of stock-based compensation in the consolidated statement of operations and comprehensive loss. The fair value of the Company’s stock option awards are estimated using a Black-Scholes option valuation model. This model requires the input of highly subjective assumptions and elections including expected stock price volatility and the estimated life of each award. In addition, the calculation of compensation costs requires that the Company estimate the number of awards that will be forfeited during the vesting period. The fair value of stock-based awards is amortized over the vesting period of the award.

Warrants	Warrants

	The Company accounts for stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Stock warrants that allow for cash settlement or provide for anti-dilution of the warrant exercise price under certain conditions are accounted for as derivative liabilities. The Company classifies derivative warrant liabilities on the balance sheet as a liability, which is revalued using a binomial options pricing model at each balance sheet date subsequent to the initial issuance. A binomial options pricing model requires the input of highly subjective assumptions and elections including expected stock price volatility and the estimated life of each award. The changes in fair value of the derivative warrant liabilities are remeasured at each balance sheet date and the resulting changes in fair value are recorded in current period earnings.

Amortization of Debt Issuance Costs	Amortization of Debt Issuance Costs

	The Company accounts for debt issuance costs in accordance with ASC 835, which allows that costs paid directly to the issuer of the notes be reported in the balance sheet as a debt discount and amortized over the term of the associated debt. Debt issuance costs associated with the senior secured note issued to Lambda on August 29, 2014 were $178,000. All of these costs, in addition to the remaining unamortized debt issuance costs related to the senior secured note issued to Lambda on November 12, 2013 of $142,000, were amortized as of December 31, 2014 and are included in interest expense on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2014.

	Total debt issuance costs recorded during the year ended December 31, 2013 were approximately $399,000. Approximately $195,000 and $204,000, respectively, were associated with the senior secured notes issued to Lambda on February 4, 2013 and November 12, 2013. Of the total debt issuance costs amortized as of December 31, 2013, approximately $53,000 and $204,000, respectively, were related to the senior secured notes issued to Lambda on February 4, 2013 and November 12, 2013 and are included in interest expense on the consolidated statements of operations and comprehensive loss.

Other Income (Expense), net	Other Income (Expense), net

	Other income of approximately $58,000 for the year ended December 31, 2014 is due to foreign currency transaction gains.

	Other expense, net, of approximately $33,000 for the year ended December 31, 2013 is primarily due to other expenses of approximately $36,000 related to foreign currency transaction losses and approximately $14,000 related to the May 2013 rights offering warrant modification. These expenses were partially offset by other income of approximately $17,000, which consisted primarily of a refund of $15,000 received as a result of the Steris agreement termination.

Income Taxes	Income Taxes

	The Company accounts for income taxes in accordance with ASC Topic 740, which requires accounting for deferred income taxes under the asset and liability method. Deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable in future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities.

	For financial reporting purposes, the Company has incurred a loss in each period since its inception. Based on available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2014 and 2013.

	ASC Topic 740 prescribes, among other things, a recognition threshold and measurement attributes for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company’s income tax return. ASC 740 utilizes a two-step approach for evaluating uncertain tax positions. Step one, or recognition, requires a company to determine if the weight of available evidence indicates a tax position is more likely than not to be sustained upon audit, including resolution of related appeals or litigation processes, if any. Step two, or measurement, is based on the largest amount of benefit, which is more likely than not to be realized on settlement with the taxing authority. The Company is subject to income tax examinations by major taxing authorities for all tax years subsequent to 2011. During the years ended December 31, 2014 and 2013, the Company recognized no adjustments for uncertain tax positions. However, management’s conclusions regarding this policy may be subject to review and adjustment at a later date based on factors including, but not limited to, on-going analyses of and changes to tax laws, regulation and interpretations, thereof.

Loss per Common Share	Net Income (loss) per Common Share

	Basic income (loss) per common share is calculated by dividing net income (loss) available to common shareholders by the number of weighted average common shares issued and outstanding. Diluted earnings (loss) per common share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares issued and outstanding for the period, plus amounts representing the dilutive effect from the exercise of stock options and warrants, as applicable. The Company calculates dilutive potential common shares using the treasury stock method, which assumes the Company will use the proceeds from the exercise of stock options and warrants to repurchase shares of common stock to hold in its treasury stock reserves.

	The following securities have been excluded from the dilutive per share computation as they are antidilutive:

		December 31,
		2014		2013
	Shares underlying options outstanding		2,472,234		2,410,134
	Shares underlying warrants outstanding		16,752,915		5,081,023
	Unvested restricted stock		132,077		75,450

Foreign Currency Translation	Foreign Currency Translation

	Foreign currency translation is recognized in accordance with ASC Topic 830. The functional currency of Nephros International Limited is the Euro and its translation gains and losses are included in accumulated other comprehensive income. The balance sheet is translated at the year-end rate. The statement of operations is translated at the weighted average rate for the year.

Comprehensive Income (Loss)	Comprehensive Income (Loss)

	Comprehensive income (loss), as defined in ASC 220, is the total of net income (loss) and all other non-owner changes in equity (or other comprehensive income (loss)). The Company’s other comprehensive income (loss) consists only of foreign currency translation adjustments.

Recent Accounting Pronouncements	Recent Accounting Pronouncements

	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, "Revenue from Contracts with Customers," related to revenue recognition. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in prior accounting guidance. ASU 2014-09 provides alternative methods of initial adoption, and it is effective for annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is not permitted. The Company is currently reviewing the revised guidance and assessing the potential impact on its consolidated financial statements.

	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.” ASU 2014-15 provides guidance about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and sets rules for how this information should be disclosed in the financial statements. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating any impact the adoption of ASU 2014-15 might have on its consolidated financial statements.

	In April 2015, the FASB issued ASU No. 2015-03, “Interest – Imputation of Interest (Subtopic 2015-03): Simplifying the Presentation of Debt Issuance Costs” related to the presentation requirements for debt issuance costs and debt discount and premium. ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by ASU 2015-03. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption of the amendments in ASU 2015-03 is permitted for financial statements that have not been previously issued. The Company does not believe that the adoption of ASU 2015-03 will have a significant impact on its consolidated financial statements.

Restatement_of_Previously_Issu1

Restatement of Previously Issued Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2014
Prior Period Adjustment [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The following table summarizes the effect of the restatement to the Company’s financial statements for (i) its audited consolidated financial statements as of and for the years ended December 31, 2013, 2012, 2011, 2010 and 2009, including the cumulative effect as of January 1, 2009, and (ii) its unaudited condensed consolidated interim financial statements as of, and for each of the quarterly periods ended, March 31, June 30, and September 30, in the years 2014 and 2013:

				(Amounts in 000s, except share and per share data)
			As
			Previously						As
			Reported			Adjustments			Restated

	Balance sheet as of September 30, 2014 (unaudited)
	Warrant Liability		$	-		$	7,116		$	7,116
	Additional Paid-in Capital			102,864			2,458			105,322
	Accumulated Deficit			-103,348			-9,573			-112,921

	Three months ended September 30, 2014 (unaudited)
	Change in fair value of warrant liability			-			3,428			3,428
	Net income (loss)			-706			3,428			2,723
	Net income (loss) per share, basic			-0.03			0.14			0.11
	Net income (loss) per share, diluted			-0.03			0.01			-0.02
	Weighted average common shares outstanding, diluted			25,238,412			8,252,777			33,491,189
	Comprehensive income (loss)			-705			3,429			2,724


				(Amounts in 000s, except share and per share data)
			As
			Previously						As
			Reported			Adjustments			Restated

	Nine months ended September 30, 2014 (unaudited)
	Change in fair value of warrant liability			-			-4,007			-4,007
	Net loss			-2,120			-4,007			-6,127
	Net income (loss) per share, basic and diluted			-0.09			-0.18			-0.27
	Comprehensive loss			-2,121			-4,007			-6,128

	Balance sheet as of June 30, 2014 (unaudited)
	Warrant Liability			-			10,544			10,544
	Additional Paid-in Capital			102,761			2,458			105,219
	Accumulated Deficit			-102,642			-13,002			-115,644

	Three months ended June 30, 2014 (unaudited)
	Change in fair value of warrant liability			-			-4,685			-4,685
	Net loss			-654			-4,685			-5,339
	Net loss per share, basic and diluted			-0.03			-0.18			-0.21
	Comprehensive loss			-655			-4,685			-5,340

	Six months ended June 30, 2014 (unaudited)
	Change in fair value of warrant liability			-			-7,436			-7,436
	Net loss			-1,414			-7,436			-8,850
	Net loss per share, basic and diluted			-0.06			-0.34			-0.4
	Comprehensive loss			-1,416			-7,436			-8,852

	Balance sheet as of March 31, 2014 (unaudited)
	Warrant Liability			-			5,859			5,859
	Additional Paid-in Capital			102,656			2,458			105,114
	Accumulated Deficit			-101,988			-8,317			-110,305

	Three months ended March 31, 2014 (unaudited)
	Change in fair value of warrant liability			-			-2,751			-2,751
	Net loss			-760			-2,751			-3,511
	Net loss per share, basic and diluted			-0.04			-0.15			-0.19
	Comprehensive loss			-761			-2,751			-3,512

	Balance sheet as of December 31, 2013 (audited)
	Warrant Liability			-			3,109			3,109
	Additional Paid-in Capital			100,526			2,457			102,983
	Accumulated Deficit			-101,228			-5,566			-106,794


			(Amounts in 000s, except share and per share data)
		As
		Previously						As
		Reported			Adjustments			Restated

Year ended December 31, 2013 (audited)
Change in fair value of warrant liability			-			5,020			5,020
Net income (loss)			-3,698			5,020			1,322
Net income (loss) per share, basic			-0.24			0.32			0.08
Net income (loss) per share, diluted			-0.24			0.06			-0.18
Weighted average common shares outstanding, diluted			15,624,999			5,135,411			20,760,410
Comprehensive income (loss)			-3,700			5,020			1,320

Balance sheet as of September 30, 2013 (unaudited)
Warrant Liability			-			7,776			7,776
Additional Paid-in Capital			100,391			2,457			102,848
Accumulated Deficit			-100,053			-10,234			-110,287

Three months ended September 30, 2013 (unaudited)
Change in fair value of warrant liability			-			-1,797			-1,797
Net loss			-611			-1,797			-2,408
Net loss per share, basic and diluted			-0.03			-0.11			-0.14
Comprehensive loss			-611			-1,797			-2,408

Nine months ended September 30, 2013 (unaudited)
Change in fair value of warrant liability			-			352			352
Net income (loss)			-2,523			352			-2,171
Net income (loss) per share, basic and diluted			-0.17			0.02			-0.15
Comprehensive loss			-2,525			352			-2,173

Balance sheet as of June 30, 2013 (unaudited)
Warrant Liability			-			5,980			5,980
Additional Paid-in Capital			100,191			2,457			102,648
Accumulated Deficit			-99,442			-8,437			-107,879

Three months ended June 30, 2013 (unaudited)
Change in fair value of warrant liability			-			-608			-608
Net loss			-671			-608			-1,279
Net loss per share, basic and diluted			-0.05			-0.05			-0.1
Comprehensive loss			-673			-608			-1,281

Six months ended June 30, 2013 (unaudited)
Change in fair value of warrant liability			-			2,149			2,149
Net income (loss)			-1,912			2,149			237
Net income (loss) per share, basic			-0.14			0.16			0.02
Net income (loss) per share, diluted			-0.14			0.04			-0.1
Weighted average common shares outstanding, diluted			14,556,050			5,150,160			19,706,210
Comprehensive income (loss)			-1,914			2,149			235

			(Amounts in 000s, except share and per share data)
		As
		Previously						As
		Reported			Adjustments			Restated

Balance sheet as of March 31, 2013 (unaudited)
Warrant Liability			-			5,372			5,372
Additional Paid-in Capital			96,988			2,457			99,445
Accumulated Deficit			-98,772			-7,830			-106,602

Three months ended March 31, 2013 (unaudited)
Change in fair value of warrant liability			-			2,756			2,756
Net income (loss)			-1,242			2,756			1,514
Net income (loss) per share, basic			-0.1			0.23			0.13
Net income (loss) per share, diluted			-0.1			0.03			-0.07
Weighted average common shares outstanding, diluted			12,009,285			5,624,075			17,633,360
Comprehensive income (loss)			-1,242			2,756			1,514

Balance sheet as of December 31, 2012 (audited)
Warrant Liability			-			8,129			8,129
Additional Paid-in Capital			96,847			2,457			99,304
Accumulated Deficit			-97,530			-10,586			-108,116

Year ended December 31, 2012 (audited)
Change in fair value of warrant liability			-			-3,361			-3,361
Net loss			-3,262			-3,361			-6,623
Net loss per share, basic and diluted			-0.29			-0.3			-0.59
Comprehensive loss			-3,262			-3,361			-6,596

Balance sheet as of December 31, 2011 (audited)
Warrant Liability			-			5,096			5,096
Additional Paid-in Capital			95,630			2,129			97,759
Accumulated Deficit			-94,268			-7,225			-101,493

Year ended December 31, 2011 (audited)
Change in fair value of warrant liability			-			-4,638			-4,638
Net loss			-2,360			-4,638			-6,998
Net loss per share, basic and diluted			-0.27			-0.54			-0.81
Comprehensive loss			-2,333			-4,638			-6,971

Balance sheet as of December 31, 2010 (audited)
Warrant Liability			-			458			458
Additional Paid-in Capital			91,979			2,129			94,108
Accumulated Deficit			-91,908			-2,587			-94,495

			(Amounts in 000s, except share and per share data)
		As
		Previously						As
		Reported			Adjustments			Restated

Year ended December 31, 2010 (audited)
Change in fair value of warrant liability			-			5,813			5,813
Net income (loss)			-1,933			5,813			3,880
Net income (loss) per share, basic and diluted			-0.93			2.79			1.86

Balance sheet as of December 31, 2009 (audited)
Warrant Liability			-			6,272			6,272
Additional Paid-in Capital			91,815			2,129			93,944
Accumulated Deficit			-89,975			-8,400			-98,375

Year ended December 31, 2009 (audited)
Change in fair value of warrant liability			-			-10,056			-10,056
Net loss			-2,026			-10,056			-12,082
Net loss per share, basic and diluted			-1.06			-5.26			-6.32

Balance sheet as of January 1, 2009 (audited)
Warrant Liability			-			2,107			2,107
Additional Paid-in Capital			90,375			-3,763			86,612
Accumulated Deficit			-87,949			1,656			-86,293

Schedule of Earnings Per Share, Basic and Diluted	As such, the diluted earnings per share calculation for those periods are calculated based upon the treasury stock method as follows:

			(restated)			(restated)			(restated)
			For the three months			For the year			For the six months
			ended September 30,			ended December 31,			ended June 30,
	(amounts in 000s, except share and per share data)		2014			2013			2013

	Loss per share – Basic:
	Numerator for basic income (loss) per share		$	2,723		$	1,322		$	237
	Denominator for basic income (loss) per share			25,238,412			15,624,999			14,556,050
	Basic income (loss) per common share		$	0.11		$	0.08		$	0.02

	Loss per share – Diluted:
	Numerator for diluted income (loss) per share		$	2,723		$	1,322			237
	Adjust: Fair value of dilutive warrants outstanding			-3,429			-5,020			-2,149
	Numerator for diluted income (loss) per share		$	-706			-3,698			-1,912

	Denominator for basic income (loss) per share			25,238,412			15,624,999			14,556,050
	Plus: Incremental shares underlying warrants outstanding			8,252,777			5,135,411			5,150,160
	Denominator for diluted income (loss) per share			33,491,189			20,760,410			19,706,210
	Diluted income (loss) per common share		$	-0.02		$	-0.18		$	-0.1

			(restated)			(restated)
			For the three months			For the year
			ended March 31,			ended December 31,
	(amounts in 000s, except share and per share data)		2013			2010

	Loss per share – Basic:
	Numerator for basic income (loss) per share		$	1,514		$	3,880
	Denominator for basic income (loss) per share			12,009,285			2,087,068
	Basic income (loss) per common share		$	0.13		$	1.86

	Loss per share – Diluted:
	Numerator for diluted income (loss) per share		$	1,514		$	3,880
	Adjust: Fair value of dilutive warrants outstanding			-2,756			-
	Numerator for diluted income (loss) per share		$	-1,242		$	3,880

	Denominator for basic income (loss) per share			12,009,285			2,087,068
	Plus: Incremental shares underlying warrants outstanding			5,624,075			-
	Denominator for diluted income (loss) per share			17,633,360			2,087,068
	Diluted income (loss) per common share		$	-0.07		$	1.86	-1

	(1)The impact of assumed exercise of warrants is not included because all of the warrants outstanding were “out of the money” during this period.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule Of Securities Excluded From Dilutive Per Share Computation	The following securities have been excluded from the dilutive per share computation as they are antidilutive:

		December 31,
		2014		2013
	Shares underlying options outstanding		2,472,234		2,410,134
	Shares underlying warrants outstanding		16,752,915		5,081,023
	Unvested restricted stock		132,077		75,450

Financial_Instruments_Tables

Financial Instruments (Tables)	12 Months Ended
Financial Instruments (Tables)	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liability measured at fair value on a recurring basis as of December 31, 2014 and 2013 (in thousands).

		Fair value measurement at reporting date using:
		Quoted prices in			Significant other			Significant		Total
		active markets			observable			unobservable
		for			inputs			inputs
		identical assets			(Level 2)			(Level 3)
		(Level 1)
	At December 31, 2014:
	Warrant liability	$	-		$	-		$	7,386	$	7,386

		Fair value measurement at reporting date using:
		Quoted prices in			Significant other			Significant		Total
		active markets			observable			unobservable
		for			inputs			inputs
		identical assets			(Level 2)			(Level 3)
		(Level 1)
	At December 31, 2013:
	Warrant liability	$	-		$	-		$	3,109	$	3,109

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The Company has issued warrants to purchase common stock that are measured at fair value on a recurring basis using unobservable inputs or available market data in a binomial options pricing model to support the fair value (Level 3). A reconciliation of the warrant liability is as follows (in thousands):

		2007 Warrants
	Balance at January 1, 2013	$	8,129
	Decrease in fair value of warrant liability		-5,020
	Balance at December 31, 2013	$	3,109
	Increase in fair value of warrant liability		4,277
	Balance at December 31, 2014	$	7,386

Fair Value Inputs, Liabilities, Quantitative Information	The following table summarizes the calculated aggregate fair values of the warrants, along with the assumptions utilized in each calculation:

		2014				2013
	Calculated aggregate value	$	7,386			$	3,109
	Weighted average exercise price	$	0.3			$	0.4
	Closing price per share of common stock	$	0.79			$	0.42
	Volatility		165.6	%			103.5	%
	Weighted average remaining expected life (years)		5.2				5
	Risk-free interest rate		1.8	%			1.6	%
	Dividend yield		-				-

Inventory_Tables

Inventory (Tables)	12 Months Ended
Inventory (Tables)	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	The Company’s inventory components as of December 31, 2014 and 2013 were as follows:

		December 31,
		2014		2013
	Total gross inventory, finished goods	$	297,000	$	527,000
	Less: inventory reserve		-111,000		-365,000
	Total inventory	$	186,000	$	162,000

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2014
Other Assets [Abstract]
Schedule Of Prepaid Expenses And Other Current Assets	Prepaid expenses and other current assets as of December 31, 2014 and 2013 were as follows:

		December 31,
		2014		2013
	Prepaid insurance premiums	$	70,000	$	70,000
	Security deposit		21,000		21,000
	Other		13,000		34,000
	Prepaid expenses and other current assets	$	104,000	$	125,000

Property_and_Equipment_Net_Tab

Property and Equipment, Net (Tables)	12 Months Ended
Property and Equipment, Net (Tables)	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and equipment as of December 31, 2014 and 2013 was as follows:

			December 31,
		Life	2014		2013
	Manufacturing equipment	3-5 years	$	599,000	$	599,000
	Research equipment	5 years		37,000		37,000
	Computer equipment	3-4 years		59,000		59,000
	Furniture and fixtures	7 years		39,000		39,000
	Property and equipment, gross			734,000		734,000
	Less: accumulated depreciation			733,000		727,000
	Property and equipment, net		$	1,000	$	7,000

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
Accrued Expenses (Tables)	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses as of December 31, 2014 and 2013 were as follows:

		December 31,
		2014		2013
	Accrued legal	$	145,000	$	149,000
	Accrued management bonus		50,000		81,000
	Accrued directors’ compensation		36,000		-
	Accrued stock transfer agent fees		27,000		-
	Accrued accounting		23,000		-
	Accrued interest		14,000		39,000
	Accrued product recall		-		60,000
	Accrued other		47,000		36,000
		$	342,000	$	365,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the income tax provision computed at the statutory tax rate to the Company’s effective tax rate is as follows:

		2014		2013
	U.S. federal statutory rate	35	%	35	%
	Warrant liability	-23.7	%	-155.1	%
	State & local taxes	5.02	%	6.4	%
	Tax on foreign operations	0.2	%	2	%
	State research and development credits	0.55	%	-3.1	%
	Other	-3.1	%	6.5	%
	Valuation allowance	-13.97	%	108.3	%
	Effective tax rate	-		-

Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets as of December 31, 2014 and 2013 are as follows:

		2014		2013
	Deferred tax assets:
	Net operating loss carry forwards	$	27,935,165	$	27,029,000
	Research and development credits		1,118,389		1,096,000
	Nonqualified stock option compensation expense		1,913,673		1,801,000
	Other temporary book - tax differences		436,178		408,000
	Total deferred tax assets		31,403,405		30,334,000
	Valuation allowance for deferred tax assets		-31,403,405		-30,334,000
	Net deferred tax assets	$	-	$	-

Stock_Plans_ShareBased_Payment1

Stock Plans, Share-Based Payments and Warrants (Tables)	12 Months Ended
Stock Plans, Share-Based Payments and Warrants (Tables)	Dec. 31, 2014
Summary Of Option Activity	The following table summarizes the option activity for the years ended December 31, 2014 and 2013:

			Shares		Weighted
					Average
					Exercise
					Price
	Outstanding at December 31, 2012		2,294,714		$	2.14
	Options granted		237,315			0.64
	Options forfeited or expired		-121,895			3.27
	Outstanding at December 31, 2013		2,410,134			1.28
	Options granted		352,519			0.5
	Options forfeited or expired		-290,419			2.45
	Outstanding at December 31, 2014		2,472,234		$	0.96

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable	The following table summarizes the options exercisable and vested and expected to vest as of December 31, 2014 and 2013:

			Shares		Weighted
					Average
					Exercise
					Price
	Exercisable at December 31, 2013		1,385,199		$	1.46
	Vested and expected to vest at December 31, 2013		2,350,688		$	1.29
	Exercisable at December 31, 2014		1,679,392		$	1.11
	Vested and expected to vest at December 31, 2014		2,426,249		$	1.04

Summary Of Information About Stock Options Outstanding And Exercisable	The following table summarizes information about stock options outstanding and exercisable at December 31, 2014:

		Options Outstanding									Options Exercisable
					Weighted
					Average						Number
		Number			Remaining				Weighted		Exercisable as
		Outstanding as			Contractual				Average		of			Weighted
	Range of Exercise	of December			Life in				Exercise		December 31,			Average
	Price	31, 2014			Years				Price		2014			Exercise Price

	$0.33 - $2.60			2,460,284			8.57		$	0.91		1,667,441		$	0.92
	$15.40 - $29.80			10,450			4.51		$	21.89		10,450		$	21.89
	$51.40-$96.00			1,500			1.58		$	64.47		1,500		$	64.47

	Total Outstanding			2,472,234					$	0.96		1,679,392		$	1.11

Schedule Of Fair Value Assumptions	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the below assumptions for the risk-free interest rates, expected dividend yield, expected lives and expected stock price volatility.

			Option Pricing Assumptions
	Grant Year		2014		2013
	Stock Price Volatility		129.8	%	129.8	%
	Risk-Free Interest Rates		1.86	%	1.36	%
	Expected Life (in years)		5.84		5.91
	Expected Dividend Yield		0	%	0	%

Summary Of Restricted Stock Activity	The following table summarizes restricted stock activity for the year end December 31, 2014 and 2013:

						Weighted
						Average
						Grant Date
			Shares			Fair Value
	Nonvested at December 31, 2012			-		$	-
	Granted			398,227			0.73
	Vested			-264,770			0.71
	Forfeited			-58,007			0.88
	Nonvested at December 31, 2013			75,450			0.66
	Granted			132,077			0.86
	Vested			-75,450			0.66
	Nonvested at December 31, 2014			132,077		$	0.86

Summary Of Terms Of Outstanding Warrants	The following table summarizes certain terms of all of the Company’s outstanding warrants at December 31, 2014 and 2013:

			Total Outstanding Warrants
										Total Common
	Title of Warrant		Date Issued		Expiry Date		Exercise Price			Shares Issuable as December 31,
										2014		2013
	Liability-classified warrants
	2007 Warrants - Lambda		11/14/07		3/21/19		$	0.3			11,742,100		8,806,575
											11,742,100		8,806,575

	Equity-classified warrants
	July 2009 Warrants		7/24/09		7/24/14		$	22.4			-		33,629
	Shareholder Rights Offering Warrants		3/10/11		3/10/16		$	0.4			2,228,238		2,264,817
	March 2011 Lambda Warrants		3/10/11		3/21/19		$	0.4			2,782,577		2,782,577
											5,010,815		5,081,023
	Total										16,752,915		13,887,598

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Contractual Obligations and Commercial Commitments	The following tables summarize our approximate minimum contractual obligations and commercial commitments as of December 31, 2014:

		Payments Due in Period
				Within		Years		Years		More than
		Total		1 Year		1 - 3		4 - 5		5 Years

	Leases	$	106,000	$	104,000	$	2,000	$	-	$	-
	Employment Contracts (1)		175,000		175,000		-		-		-
	Total	$	281,000	$	279,000	$	2,000	$	-	$	-

	(1) Represents amount payable under severance agreement for John C. Houghton, effective January 4, 2015. See Note 15, Subsequent Events, for further discussion.

Organization_and_Nature_of_Ope1

Organization and Nature of Operations (Details Textual)	12 Months Ended
Organization and Nature of Operations (Details Textual)	Dec. 31, 2014
Organization And Nature Of Operations [Line Items]
Number Of Products In Development	2

Restatement_of_Previously_Issu2

Restatement of Previously Issued Financial Statements (Details) (USD $)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2014	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010		Dec. 31, 2009	Jan. 01, 2009
Warrant Liability	$7,116	$10,544	$5,859	$7,776	$5,980	$5,372	$10,544	$5,980	$7,116	$7,776	$7,386	$3,109	$8,129	$5,096	$458		$6,272	$2,107
Additional Paid-in Capital	105,322	105,219	105,114	102,848	102,648	99,445	105,219	102,648	105,322	102,848	108,382	102,983	99,304	97,759	94,108		93,944	86,612
Accumulated Deficit	-112,921	-115,644	-110,305	-110,287	-107,879	-106,602	-115,644	-107,879	-112,921	-110,287	-114,165	-106,794	-108,116	-101,493	-94,495		-98,375	-86,293
Change in fair value of warrant liability	3,428	-4,685	-2,751	-1,797	-608	2,756	-7,436	2,149	-4,007	352	4,277	-5,020	-3,361	-4,638	5,813		-10,056
Net income (loss)	2,723	-5,339	-3,511	-2,408	-1,279	1,514	-8,850	237	-6,127	-2,171	-7,371	1,322	-6,623	-6,998	3,880		-12,082
Net income (loss) per share, basic	$0.11					$0.13		$0.02			($0.31)	$0.08			$1.86
Net income (loss) per share, diluted	($0.02)					($0.07)		($0.10)			($0.31)	($0.18)			$1.86	[1]
Net income (loss) per share, basic and diluted		($0.21)	($0.19)	($0.14)	($0.10)	($0.07)	($0.40)		($0.27)	($0.15)		($0.18)	($0.59)	($0.81)	$1.86		($6.32)
Weighted average common shares outstanding, diluted	33,491,189					17,633,360		19,706,210				20,760,410
Comprehensive income (loss)	2,724	-5,340	-3,512	-2,408	-1,281	1,514	-8,852	235	-6,128	-2,173	-7,373	1,320	-6,596	-6,971
Scenario, Previously Reported [Member]
Warrant Liability	0	0	0	0	0	0	0	0	0	0		0	0	0	0		0	0
Additional Paid-in Capital	102,864	102,761	102,656	100,391	100,191	96,988	102,761	100,191	102,864	100,391		100,526	96,847	95,630	91,979		91,815	90,375
Accumulated Deficit	-103,348	-102,642	-101,988	-100,053	-99,442	-98,772	-102,642	-99,442	-103,348	-100,053		-101,228	-97,530	-94,268	-91,908		-89,975	-87,949
Change in fair value of warrant liability	0	0	0	0	0	0	0	0	0	0		0	0	0	0		0
Net income (loss)	-706	-654	-760	-611	-671	-1,242	-1,414	-1,912	-2,120	-2,523		-3,698	-3,262	-2,360	-1,933		-2,026
Net income (loss) per share, basic	($0.03)					($0.10)		($0.14)				($0.24)
Net income (loss) per share, diluted	($0.03)							($0.14)
Net income (loss) per share, basic and diluted		($0.03)	($0.04)	($0.03)	($0.05)	($0.10)	($0.06)		($0.09)	($0.17)		($0.24)	($0.29)	($0.27)	($0.93)		($1.06)
Weighted average common shares outstanding, diluted	25,238,412					12,009,285		14,556,050				15,624,999
Comprehensive income (loss)	-705	-655	-761	-611	-673	-1,242	-1,416	-1,914	-2,121	-2,525		-3,700	-3,262	-2,333
Restatement Adjustment [Member]
Warrant Liability	7,116	10,544	5,859	7,776	5,980	5,372	10,544	5,980	7,116	7,776		3,109	8,129	5,096	458		6,272	2,107
Additional Paid-in Capital	2,458	2,458	2,458	2,457	2,457	2,457	2,458	2,457	2,458	2,457		2,457	2,457	2,129	2,129		2,129	-3,763
Accumulated Deficit	-9,573	-13,002	-8,317	-10,234	-8,437	-7,830	-13,002	-8,437	-9,573	-10,234		-5,566	-10,586	-7,225	-2,587		-8,400	1,656
Change in fair value of warrant liability	3,428	-4,685	-2,751	-1,797	-608	2,756	-7,436	2,149	-4,007	352		5,020	-3,361	-4,638	5,813		-10,056
Net income (loss)	3,428	-4,685	-2,751	-1,797	-608	2,756	-7,436	2,149	-4,007	352		5,020	-3,361	-4,638	5,813		-10,056
Net income (loss) per share, basic	$0.14					$0.23		$0.16				$0.32
Net income (loss) per share, diluted	$0.01							$0.04
Net income (loss) per share, basic and diluted		($0.18)	($0.15)	($0.11)	($0.05)	$0.03	($0.34)		($0.18)	$0.02		$0.06	($0.30)	($0.54)	$2.79		($5.26)
Weighted average common shares outstanding, diluted	8,252,777					5,624,075		5,150,160				5,135,411
Comprehensive income (loss)	$3,429	($4,685)	($2,751)	($1,797)	($608)	$2,756	($7,436)	$2,149	($4,007)	$352		$5,020	($3,361)	($4,638)

[1]	The impact of assumed exercise of warrants is not included because all of the warrants outstanding were "out of the money" during this period.

Restatement_of_Previously_Issu3

Restatement of Previously Issued Financial Statements (Schedule of Earnings Per Share, Basic and Diluted) (Details) (USD $)	3 Months Ended		6 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2013	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2010
Loss per share - Basic:
Numerator for basic income (loss) per share	$2,723	$1,514	$237		$1,322	$3,880
Denominator for basic income (loss) per share	25,238,412	12,009,285	14,556,050	23,817,184	15,624,999	2,087,068
Basic income (loss) per common share	$0.11	$0.13	$0.02	($0.31)	$0.08	$1.86
Loss per share - Diluted:
Numerator for diluted income (loss) per share	2,723	1,514	237		1,322	3,880
Adjust: Fair value of dilutive warrants outstanding	-3,429	-2,756	-2,149		-5,020	0
Numerator for diluted income (loss) per share	($706)	($1,242)	($1,912)		($3,698)	$3,880
Denominator for basic income (loss) per share	25,238,412	12,009,285	14,556,050	23,817,184	15,624,999	2,087,068
Plus: Incremental shares underlying warrants outstanding	8,252,777	5,624,075	5,150,160		5,135,411	0
Denominator for diluted income (loss) per share	33,491,189	17,633,360	19,706,210	23,817,184	20,760,410	2,087,068
Diluted income (loss) per common share	($0.02)	($0.07)	($0.10)	($0.31)	($0.18)	$1.86	[1]

[1]	The impact of assumed exercise of warrants is not included because all of the warrants outstanding were "out of the money" during this period.

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Schedule Of Securities Excluded From Dilutive Per Share Computation) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded anti-dilutive stock options and warrants	16,752,915	5,081,023
Unvested restricted stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded anti-dilutive stock options and warrants	132,077	75,450
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded anti-dilutive stock options and warrants	2,472,234	2,410,134

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual)

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Dec. 18, 2014

Mar. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Nov. 12, 2013

Feb. 04, 2013

Dec. 31, 2013

Aug. 29, 2014

Nov. 12, 2013

Feb. 04, 2013

Aug. 29, 2014

Dec. 31, 2013

Dec. 31, 2014

Apr. 04, 2014

Feb. 19, 2014

Dec. 31, 2014

USD ($)

Sales Revenue [Member]

Accounts Receivable [Member]

Senior Notes [Member]

Warrant [Member]

Lambda Investors [Member]

Steris Agreement Termination [Member]

Nonsoftware License Arrangement [Member]

Bellco [Member]

USD ($)

Senior Notes [Member]

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

Basis Of Presentation And Going Concern [Line Items]

Upfront Fees And Connection Of First Amendment

€ 225,000

$612,000

€ 450,000

Proceeds from issuance of common stock

3,000,000

2,100,000

4,866,000

2,771,000

Deferred Revenue

487,000

703,000

Licenses Revenue

834,000

711,000

2,589,000

Recognition of Deferred Revenue

487,000

Shipping, Handling and Transportation Costs

4,000

5,000

Amortization of debt issuance costs

142,000

399,000

204,000

53,000

178,000

204,000

195,000

Other Nonoperating Income (Expense), Total

58,000

-33,000

Adjustments to liabilities and foreign currency losses

36,000

14,000

Interest and Other Income

17,000

15,000

Debt Instrument, Face Amount

1,750,000

Allowance for Doubtful Accounts Receivable

1,000

Allowance for Doubtful Accounts Receivable, Write-offs

Sales Returns and Allowances, Goods

Concentration Risk, Percentage

78.00%

86.00%

83.00%

97.00%

Number Of Major Customers

Financial_Instruments_Details

Financial Instruments (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$7,386	$3,109
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$7,386	$3,109

Financial_Instruments_Details_

Financial Instruments (Details 1) (USD $)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2014	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Jan. 01, 2009
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant Liability	$7,116	$10,544	$5,859	$7,776	$5,980	$5,372	$10,544	$5,980	$7,116	$7,776	$7,386	$3,109	$8,129	$5,096	$458	$6,272	$2,107
Increase Decrease In Warrant Liability	3,428	-4,685	-2,751	-1,797	-608	2,756	-7,436	2,149	-4,007	352	4,277	-5,020	-3,361	-4,638	5,813	-10,056
2007 Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrant Liability											7,386	3,109	8,129
Increase Decrease In Warrant Liability											$4,277	($5,020)

Financial_Instruments_Details_1

Financial Instruments (Details 2) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Calculated aggregate value	$7,386	$3,109
Weighted average exercise price	$0.30	$0.40
Closing price per share of common stock	$0.79	$0.42
Volatility	165.60%	103.50%
Weighted average remaining expected life (years)	5 years 2 months 12 days	5 years
Risk-free interest rate	1.80%	1.60%
Dividend yield	0.00%	0.00%

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Total gross inventory, finished goods	$297,000	$527,000
Less: inventory reserve	-111,000	-365,000
Total inventory	$186,000	$162,000

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Prepaid Expenses and Other Current Assets [Line Items]
Prepaid insurance premiums	$70,000	$70,000
Security deposit	21,000	21,000
Other	13,000	34,000
Prepaid expenses and other current assets	$104,000	$125,000

Property_and_Equipment_Net_Sch

Property and Equipment, Net (Schedule Of Property and Equipment, Net) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$734,000	$734,000
Less: accumulated depreciation	733,000	727,000
Property and equipment, net	1,000	7,000
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	599,000	599,000
Manufacturing equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Life	3 years
Manufacturing equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Life	5 years
Research equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	37,000	37,000
Property and equipment, Life	5 years
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	59,000	59,000
Computer equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Life	3 years
Computer equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Life	4 years
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$39,000	$39,000
Property and equipment, Life	7 years

Property_and_Equipment_Net_Det

Property and Equipment, Net (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Depreciation, Depletion and Amortization	$6	$9
Gain (Loss) on Disposition of Property Plant Equipment, Total	$0	$3

Senior_Secured_Notes_Details_T

Senior Secured Notes (Details Textual) (USD $)	1 Months Ended	0 Months Ended	1 Months Ended		12 Months Ended
Senior Secured Notes (Details Textual) (USD $)	Mar. 21, 2014	Nov. 12, 2013	Aug. 29, 2014	22-May-13	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Legal fees	$128,000
Amortization of debt discount (premium)		195,000	177,000	204,000	320,000	257,000
Interest Expense, Debt					178,000
Interest Expense					483,000	351,000
Senior Notes [Member]
Debt Instrument [Line Items]
Transaction fees			140,000
Interest Expense					142,000	53,000
Lambda Investors LLC [Member] \| Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		1,500,000	1,750,000
Debt instrument, interest rate, stated percentage		12.00%	12.00%
Debt instrument, maturity date		12-May-14	28-Feb-15
Percentage of sourcing fees		8.00%	8.00%
Transaction fees		120,000
Legal fees		$75,000	$38,000

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses [Line Items]
Accrued legal	$145,000	$149,000
Accrued management bonus	50,000	81,000
Accrued Directorsb Compensation	36,000	0
Accrued stock transfer agent fees	27,000
Accrued accounting	23,000
Accrued interest	14,000	39,000
Accrued product recall	0	60,000
Accrued other	47,000	36,000
Accrued expenses	$342,000	$365,000

Income_Taxes_Details

Income Taxes (Details)	12 Months Ended
Income Taxes (Details)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Holiday [Line Items]
U.S. federal statutory rate	35.00%	35.00%
Warrant liability	-23.70%	-155.10%
State & local taxes	5.02%	6.40%
Tax on foreign operations	0.20%	2.00%
State research and development credits	0.55%	-3.10%
Other	-3.10%	6.50%
Valuation allowance	-13.97%	108.30%
Effective tax rate	0.00%	0.00%

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carry forwards	$27,935,165	$27,029,000
Research and development credits	1,118,389	1,096,000
Nonqualified stock option compensation expense	1,913,673	1,801,000
Other temporary book - tax differences	436,178	408,000
Total deferred tax assets	31,403,405	30,334,000
Valuation allowance for deferred tax assets	-31,403,405	-30,334,000
Net deferred tax assets	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
Income Taxes (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Research Tax Credit Carryforward [Member]
Income Tax [Line Items]
Tax Credit Carryforward, Amount	1,118,389	$1,096,000
Federal And New Jersey [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	92,928,000
Foreign [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	8,070,000
Foreign [Member] \| Minimum [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	31-Dec-14
Foreign [Member] \| Maximum [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	31-Dec-26

Stock_Plans_ShareBased_Payment2

Stock Plans, Share-Based Payments and Warrants (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding at beginning of year	2,410,134	2,294,714
Shares, Options granted	352,519	237,315
Options forfeited or expired	-290,419	-121,895
Shares, Outstanding at end of year	2,472,234	2,410,134
Shares, Exercisable at end of year	1,679,392	1,385,199
Shares, Vested and expected to vest	2,426,249	2,350,688
Weighted Average Exercise Price, Outstanding at beginning of year	$1.28	$2.14
Weighted Average Exercise Price, Options granted	$0.50	$0.64
Weighted Average Exercise Price, Options forfeited or expired	$2.45	$3.27
Weighted Average Exercise Price, Outstanding at end of year	$0.96	$1.28
Weighted Average Exercise Price, Exercisable at end of year	$1.11	$1.46
Weighted Average Exercise Price, Vested and expected to vest at end of year	$1.04	$1.29

Stock_Plans_ShareBased_Payment3

Stock Plans, Share-Based Payments and Warrants (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Exercisable	1,679,392	1,385,199
Shares, Vested and expected to vest	2,426,249	2,350,688
Weighted Average Exercise Price, Exercisable	$1.11	$1.46
Weighted Average Exercise Price, Vested and expected to vest	$1.04	$1.29

Stock_Plans_ShareBased_Payment4

Stock Plans, Share-Based Payments and Warrants (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding as of December 31, 2013	2,472,234
Options Outstanding, Weighted Average Exercise Price	$0.96
Options Exercisable, Number Exercisable as of December 31, 2013	1,679,392
Options Exercisable, Weighted Average Exercise Price	$1.11
$0.33 - $2.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Range	$0.33
Range of Exercise Price, Upper Range	$2.60
Options Outstanding, Number Outstanding as of December 31, 2013	2,460,284
Options Outstanding, Weighted Average Remaining Contractual Life In Years	8 years 6 months 25 days
Options Outstanding, Weighted Average Exercise Price	$0.91
Options Exercisable, Number Exercisable as of December 31, 2013	1,667,441
Options Exercisable, Weighted Average Exercise Price	$0.92
$15.40 - $29.80
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Range	$15.40
Range of Exercise Price, Upper Range	$29.80
Options Outstanding, Number Outstanding as of December 31, 2013	10,450
Options Outstanding, Weighted Average Remaining Contractual Life In Years	4 years 6 months 4 days
Options Outstanding, Weighted Average Exercise Price	$21.89
Options Exercisable, Number Exercisable as of December 31, 2013	10,450
Options Exercisable, Weighted Average Exercise Price	$21.89
$51.40-$96.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Range	$51.40
Range of Exercise Price, Upper Range	$96
Options Outstanding, Number Outstanding as of December 31, 2013	1,500
Options Outstanding, Weighted Average Remaining Contractual Life In Years	1 year 6 months 29 days
Options Outstanding, Weighted Average Exercise Price	$64.47
Options Exercisable, Number Exercisable as of December 31, 2013	1,500
Options Exercisable, Weighted Average Exercise Price	$64.47

Stock_Plans_ShareBased_Payment5

Stock Plans, Share-Based Payments and Warrants (Details 3)	12 Months Ended
Stock Plans, Share-Based Payments and Warrants (Details 3)	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Volatility	129.80%	129.80%
Risk-Free Interest Rates	1.86%	1.36%
Expected Life (in years)	5 years 10 months 2 days	5 years 10 months 28 days
Expected Dividend Yield	0.00%	0.00%

Stock_Plans_ShareBased_Payment6

Stock Plans, Share-Based Payments and Warrants (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Shares, Granted	352,519	237,315
Weighted Average Grant Date Fair Value, Granted	$0.45	$0.56
Restricted Stock [Member]
Class of Warrant or Right [Line Items]
Shares, Nonvested	75,450	0
Shares, Granted	132,077	398,227
Shares, Vested	-75,450	-264,770
Shares, Forfeited		-58,007
Shares, Nonvested	132,077	75,450
Weighted Average Grant Date Fair Value, Nonvested	$0.66	$0
Weighted Average Grant Date Fair Value, Granted	$0.86	$0.73
Weighted Average Grant Date Fair Value, Vested	$0.66	$0.71
Weighted Average Grant Date Fair Value, Forfeited		$0.88
Weighted Average Grant Date Fair Value, Nonvested	$0.86	$0.66

Stock_Plans_ShareBased_Payment7

Stock Plans, Share-Based Payments and Warrants (Details 5) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Nov. 10, 2014	Feb. 14, 2014	17-May-13
Class of Warrant or Right [Line Items]
Exercise Price	$0.45	$0.33	$0.60	$0.30	$0.60
Total Common Shares Issuable	5,081,023	5,010,815
July 2009 Warrants [Member]
Class of Warrant or Right [Line Items]
Date Issued	24-Jul-09
Expiry Date	24-Jul-14
Exercise Price	$22.40
Total Common Shares Issuable	33,629	0
2007 Warrants - Lambda [Member]
Class of Warrant or Right [Line Items]
Date Issued	14-Nov-07
Expiry Date	21-Mar-19
Exercise Price	$0.30
Total Common Shares Issuable	8,806,575	11,742,100
Shareholder Rights Offering Warrants [Member]
Class of Warrant or Right [Line Items]
Date Issued	10-Mar-11
Expiry Date	10-Mar-16
Exercise Price	$0.40
Total Common Shares Issuable	2,264,817	2,228,238
March 2011 Lambda Warrants [Member]
Class of Warrant or Right [Line Items]
Date Issued	10-Mar-11
Expiry Date	21-Mar-19
Exercise Price	$0.40
Total Common Shares Issuable	2,782,577	2,782,577

Stock_Plans_ShareBased_Payment8

Stock Plans, Share-Based Payments and Warrants (Details Textual) (USD $)	1 Months Ended			12 Months Ended
	Dec. 18, 2014	Mar. 21, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 10, 2014	Feb. 14, 2014	17-May-13	Mar. 31, 2011	Mar. 15, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
options outstanding				2,472,234	2,410,134	2,294,714
Share-based compensation expense				$421,000	$418,000
Fair value of options vested				507,000	519,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				352,519	237,315
Weighted-average fair value of options granted				$0.45	$0.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value				241,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value				235,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term				7 years 6 months	8 years 1 month 6 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options				504,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				1 year 10 months 24 days
Class of Warrant or Right, Exercise Price of Warrants or Rights				$0.33	$0.45		$0.60	$0.30	$0.60
Warrants Exercised				791,278	2,254,500
Stock Issued During Period, Shares, New Issues		7,140,823		36,570
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments, Total				15,000	248,000
Proceeds from Issuance of Common Stock	3,000,000		2,100,000	4,866,000	2,771,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options				8,000
Additional Shares Not Issued Results Of Warrants Exercised					374
Shareholders' Equity [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$0.40
Right Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercised					14,879,708
Stock Issued During Period, Shares, New Issues					687,793
Proceeds from Issuance of Common Stock					206,000
Incremental Fair Value of Inducement					14,000
Right Offering [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$0.40
Right Offering [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$0.30
Class D Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$0.40
Warrants Exercised						8,806,575
Stock Issued During Period, Shares, Conversion of Convertible Securities						11,742,100
Warrants Exercised Under Cashless Exercise Provision						$0.30
Class D Warrant Lambda [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					11,742,100
Class of Warrant or Right, Date from which Warrants or Rights Exercisable					21-Mar-19
Shareholder Rights Offering Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercised					104,206
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments, Total					42,000
CEO Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued				331,550	331,550
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				132,077	398,227
Weighted-average fair value of options granted				$0.86	$0.73
Share-based compensation expense				$109,000
2000 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance				106,538
options outstanding											2,834
2000 Plan [Member] \| Non Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance				106,538
2004 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance				4,500,000
Shares available for future grants				2,054,799	2,407,318
2004 Plan [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
options outstanding				1,236,975	1,028,509
2004 Plan [Member] \| Non Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
options outstanding				903,709	715,692
Shares available for future grants				903,709	715,692

Stockholders_Deficit_Details_T

Stockholders' Deficit (Details Textual) (USD $)	1 Months Ended			0 Months Ended	1 Months Ended	12 Months Ended
Stockholders' Deficit (Details Textual) (USD $)	Dec. 18, 2014	Aug. 29, 2014	Mar. 21, 2014	Nov. 12, 2013	22-May-13	Dec. 31, 2014	Dec. 31, 2013	Nov. 10, 2014	Oct. 20, 2014	Feb. 14, 2014	Jan. 07, 2014	17-May-13	Mar. 04, 2013
Stockholder Equity Note [Line Items]
Authorized value of rights offering									$3,000,000		$2,800,000		$3,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								0.11901		0.28673		0.18776
Class of warrant or right issued, shares	5,000,000				5,000,000
Class of warrant or right issued gross value received	3,000,000		2,100,000		3,000,000
Class of warrant or right issued net value received	1,100,000		581,000		1,400,000
Repayments of accrued interest on senior secured note	64,000		61,000		46,800
Class of Warrant or Right, Exercise Price of Warrants or Rights						$0.33	$0.45	$0.60		$0.30		$0.60
Debt Instrument, Fee Amount					104,000
Reimbursement of legal fee	75,000				100,000
Amortization of debt discount (premium)		177,000		195,000	204,000	320,000	257,000
Repayments of Senior Debt	1,750,000		1,500,000		1,300,000	3,250,000	1,300,000
Subscription rights percentage			77.00%
Common stock of subscription rights			7,140,823			36,570
Legal fees			$128,000

401k_Plan_Details_Textual

401(k) Plan (Details Textual) (USD $)	12 Months Ended		1 Months Ended
401(k) Plan (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Jan. 01, 2004
Defined Benefit Plan Disclosure [Line Items]
Maximum employee contribution, percentage	15.00%
Contribution expense	$43,000	$46,000
3% Employee Contribution [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution, percentage			100.00%
Percent of employee contributions matched by employer			3.00%
2% Employee Contribution [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution, percentage			50.00%
Percent of employee contributions matched by employer			2.00%

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Dec. 31, 2014
Commitments And Contingencies [Line Items]
Payments Due, Total	$281,000
Payments Due Within 1 Year	279,000
Payments Due Within 1 - 3 Years	2,000
Payments Due Within 4 - 5 Years	0
Payments Due More Than 5 Years	0
Leases [Member]
Commitments And Contingencies [Line Items]
Payments Due, Total	106,000
Payments Due Within 1 Year	104,000
Payments Due Within 1 - 3 Years	2,000
Payments Due Within 4 - 5 Years	0
Payments Due More Than 5 Years	0
Employment Contracts [Member]
Commitments And Contingencies [Line Items]
Payments Due, Total	175,000	[1]
Payments Due Within 1 Year	175,000	[1]
Payments Due Within 1 - 3 Years	0	[1]
Payments Due Within 4 - 5 Years	0	[1]
Payments Due More Than 5 Years	$0	[1]

[1]	Represents amount payable under severance agreement for John C. Houghton, effective January 4, 2015. See Note 15, Subsequent Events, for further discussion.

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual)

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Jul. 25, 2013

Dec. 31, 2014

Dec. 31, 2013

Aug. 27, 2014

Nov. 30, 2013

Dec. 31, 2013

Apr. 04, 2014

Feb. 19, 2014

Dec. 31, 2014

Feb. 04, 2013

23-May-13

Apr. 23, 2012

Dec. 31, 2014

USD ($)

EUR (€)

USD ($)

Product Recall [Member]

Bellco [Member]

Medica S.p.A [Member]

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

Commitments And Contingencies [Line Items]

Number of units under first tier royalty receivable

125,000

First tier royalty per unit

2.4

1.75

Second tier royalty per unit

1.71

1.25

Upfront Fees And Connection Of First Amendment

€ 225,000

$612,000

€ 450,000

License agreement product purchases in year one

400,000

300,000

License agreement product purchases in year two

700,000

500,000

License agreement product purchases in year three

880,000

750,000

Purchase commitment

900,000

766,000

License agreement first installment payment

700,000

500,000

License agreement second installment payment

800,000

600,000

License agreement final installment payment

500,000

400,000

License agreement options to purchase shares

300,000

Fair value of stock options granted to Medica

273,000

Other assets, net of accumulated amortization

1,684,000

1,894,000

Accumulated amortization

566,000

Amortization of Other Deferred Charges

210,000

214,000

Amortization expense, years two and three

210,000

Royalty rate

3.00%

Monthly rent expense

8,000

Cost of goods sold

549,000

898,000

110,000

Sales revenue

914,000

1,029,000

216,000

Rent expense

117,000

116,000

Future renewed monthly rent expense

8,800

Lease extension term

1 year

6 months

License agreement payment

2,000,000

1,500,000

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Interest Expense, Lessee, Assets under Capital Lease

$600

€ 500

Notice Period on Lease Agreement

2 months